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The MCV Quarterly ceases publication with this issue. No 
journal of this type can be self-supporting and we bow to the inevi-
table reality of inflation. 
The idea of the Quarterly came from Sarni Sa"id. Almost single 
handed he cajoled and coerced the Dean of the School of Medicine 
into .finding the money for publication. Throughout its existence 
MCV /Q has remained true to its stated purpose of disseminating 
"scientific information from all sources'~ resisting several attempts 
to convert it into a "house journal" or popular newssheet. In essence, 
it has been the printed pivot of continuing education in the medical 
school. 
It is hard to name the people behind the success, albeit tempo-
rary, of MCV /Q. The editors, of course-Sarni Said and Fair 
Goodale-but even more so the Managing Editors-the last of whom 
was Mary Park Johnson; the cover designer--Raymond Geary-
whose eye catching, balanced designs have been a feature of the 
Quarterly since its inception; and.finally, the Deans of the School of 
Medicine-Drs. Kinloch Nelson, Warren Pierse, andjesse Steinfeld. 
"Publish or perish" is an aca,demic aphorism today. Regret-
fully, we perish-but at least we published for sixteen enjoyable 
years. 
FJS 
THE MEDICAL COLLEGE OF VIRGINIA 
SCHOOL OF MEDICINE 
Continuing Education Programs for 1982 
DERMATOLOGY AND INTERNAL MEDICINE 
Date: February 12-14, 1982 
Location: The Homestead, Hot Springs, Virginia 
Tuition and Fees: $220.000 
A first time presentation providing the dermatologist and the internist with current concepts in diagnosis 
and management of skin disorders with systemic manifestations and systemic diseases involving the 
skin. The format includes lecture, discussion, and workshops. 
PEDIATRIC RADIOLOGY 
Date: February 28-March 4, 1982 
Location: The Williamsburg Lodge, Williamsburg , Virginia 
Tuition and Fees: $330.00 
Radiologists and other treating pediqtric diseases are presented with the newer techniques available in 
diagnosis. Some of the topics include Ultrasound, UT!, Pneumonia, Generalized Orthopedic Diseases 
and Lesions of the Lungs. 
RETINAL DISEASES AND OCULAR TUMORS 
Date: March 19-21, 1982 
Location: The Williamsburg Lodge, Williamsburg, Virginia 
Tuition and Fees: $250.00 · 
An in-depth exploration of the clinical diagnosis and management of retinal disease and ocular tumors. 
Practicing ophthalmologists are invited to hear lectures, participate in small group sessions, and bring 
difficult cases for consultation with MCV and guest faculty. 
CLINICAL CONCERNS IN PRIMARY CARE 
Date: April 16-18, 1982 
Location: The Hospitality House, Williamsburg, Virginia 
Tuition and Fees: $225.00 
Primary care physicians are involved in workshops planned around three major areas of concern: 
hematology, infectious qisease, and oncology. Topics include: anemias, work-up and management of 
the bleeding patient, upper respiratory infections, abuse of antibiotics, treatable cancers and early 
diagnosis, and management of common cancers. 
SPRINGFEST: A CME PROGRAM IN PEDIATRICS 
Date: April 22-24, 1982 
Location: The Hospitality House, Williamsburg, Virginia 
Tuition and Fees: To be announced 
Behavioral aspects, dermatology, office emergencies, and other selected topics are explored for new 
clinical information, implications, issues, and answers. Pediatricians share in le9tures, discussions, and 
small group sessions. 
EMERGENCY MEDICINE 
Date: April 23-25, 1982 
Location: Quality Inn-Fort Magruder, Williamsburg, Virginia 
Tuition and Fees: $195.00 
Lectures and workshops designed to provide emergency room and office based physicians with 
practical clinical approaches to basic medical and surgical emergencies. Some of the topics are 
sprains/strains, common anorectal problems, cardiac drugs, arrhythmias, splinting , and suture tech-
niques. · 
HANS BERGER DAY: EEG SYMPOSIUM 
Date: May 17- 18, 1982 
Location: Baruch Auditorium, Richmond, Virginia 
Tu ition and Fees: To be announced 
Designed for physicians and other health professionals who use EEG as a diagnostic tool. Topics 
include intractable seizures, cerebral death , stroke, and degenerative diseases of the brain. 
RECENT TRENDS IN CLINICAL RADIATION ONCOLOGY 
Date: May 20- 22 , 1982 
Location: The Hospitality House, Williamsburg , Virginia 
Tuition and Fees: $250.00 
For physicians involved in the management of cancer. Lectures and small group sessions address 
childhood cancer, Hodgkins Disease, Non-Hodgkin Lymphoma, prostate , cervix , ovarian , paranasal, 
recto-sigmoid , breast, larnyx, and testicular carcinoma. 
GYNECOLOGIC UROLOGY AND PELVIC SURGERY 
Date: May 29- 31 , 1982 
Location: The Homestead , Hot Springs, Virginia 
Tuition and Fees: To be announced 
Reviews basic and advanced concepts in gynecologic urology and pelvic surgery. Formal presentations 
and small group sessions allow for didactic and direct exchange of information. 
CARDIOLOGY 
Date: June 18- 20, 1982 
Location: The Hospitality House, Williamsburg, Virginia 
Tuition and Fees: $230.00 
For those who practice cardiology. Small group sessions highlight important information : deciding about 
valvular heart surgery, hypertrophic myopathies, drug management of ventricular arrhythmias, interven-
tion with acute myocardial infarct, and recent advances in treating heart failure. 
PEDIATRICS AT THE BEACH 
Date: August 4-7 , 1982 
Location: Sheration Beach Inn , Virginia Beach , Virginia 
Tuition and Fees: $235.00 
Allergy, immunology, dermatology, and orthopedics for the practicing pediatrician . Lectures and small 
group sessions designed to provide clinical insight into topics such as persistent urticaria, steroids and 
asthma, fungal dermatoses, and common orthopedic problems. 
SUMMER RETREAT: PRACTICAL ISSUES IN PRIMARY CARE 
Date: August 11-14, 1982 
Location : Sheraton Beach Inn , Virginia Beach , Virginia 
Tuition and Fees: $235.00 
For the family physician, the general practitioner, the physician delivering primary care. Lectures and 
discussion providing doctors with opportunities to discuss issues in cardiology, management of pain , 
antibiotics in medicine and surgery, and medical malpractice. 
The Medical College of Virginia (MCV) is the State's major provider of continuing medical education 
conferences and institutes. Two thousand physicians from across the United States participated in MCV 
programs during 1980-81. Nationally known MCV faculty and distinguished guest faculty share medical 
insights on the most recent and successful diagnostic and therapeutic techniques. Participants are 
encouraged to share problem cases. Leisurely surroundings, informed practitioners , and involved faculty 
blend effectively to create pleasant and meaningful experiences in continued learning. 
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The Gay Nineties: Oscar Wilde 
Reconsidered 
FREDERICK J. SPENCER, MD 
Pro fessor and Chairman, Department of Preventive Medicine, Medical College of Virginia , Health 
Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
Sex and hypocrisy have always been bed-
mates, but never more than in Victorian Eng-
land. In the " Gay Nineties" promiscuity was 
widely accepted in all social classes, although 
the aristocracy hid its lust behind a strict code of 
propriety. Country house parties catered to in-
fidelities with the approval of the Prince of 
Wales , himself a notorious womanizer . 
The sexual athleticism of His Royal High-
ness , Albert Edward, has been covered in innu-
merable books. 1 Protected from women by the 
vigilance of his mother until he was 20 years 
old, he was introduced to the delights of the bed 
in Ireland by an actress/camp follower of the 
Grenadier Guards. The bevy of mistresses that 
followed resulted in one court case and several · 
minor scandals . His future queen , Alexandria , 
withstood his dalliances with dignity, finally 
sending for Mrs Alice Keppel, his last and firm-
est mistress, when he was on his death bed, re-
marking at the same time that "He always loved 
me the best ." 
In 1890, the word "gay" was used for 
heterosexual relationships with prostitutes , 
today 's use not coming into effect until the 
1 930s, and only into common use in the past 
ten to 1 5 years. 2 The "Gay Lothario" of 1 7 0 3 
was certainly no homosexual. 3 So the "Gay 
Nineties '' were very gay indeed, in the old-fash-
ioned sense of the word. As Mrs Patrick Camp-
bell is supposed to have said , "You can do 
what you like as long as you don't frighten the 
horses.'' But sodomy was another matter. This 
most despicable crime of all-the ''abominable 
crime of buggery ' '-was the indictment 
brought against Oscar Wilde in 1895. 4 
Oscar Fingal O'Flahertie Wills Wilde was 
born in Dublin, Ireland on 16 October 1854. 
His father, Sir William Wilde , the son of a 
doctor, was a pioneer otorhinolaryngologist and 
opthalmologist , a combination of specialties 
which existed well into the twentieth century . 
Among Sir William 's innovations were angled 
nasal forceps and "Wilde's Incision ," a deep 
opening of the mastoid air cells in the treatment 
of acute mastoiditis. 5 He was also a noted Irish 
antiquary and archaeologist. Unprofessionally , 
his sexual promiscuity led to several illegitimate 
children and to a prosecution for molesting a fe-
male patient of dubious virtue; she was 
awarded % d in damages-the smallest pos-
sible sum! 
Oscar Wilde's mother, known as Spe-
ranza, was an accomplished poet and the au-
thor of several revolutionary pamphlets, a suf-
ficient reason for her nom-de-plume, even if 
women authors had been socially acceptable in 
the 1850s.6 Oscar was the second of Lady 
Wilde's children , and his elder brother, William , 
later known as " Wuffalo Will ," became a notori-
ous and intemperate man-about-town . 7 It is said 
that Oscar 's mother wanted a daughter and 
showed her disappointment by dressing him in 
girl 's clothes until the birth of her third child, a 
daughter, Isola, when Oscar was three years 
old. 8 Much has been made of a picture of Wilde 
in a girl 's dress at the age of two , the infer-
ence being that it was a conditioning factor in 
his homosexuality, but it is doubtful if it played a 
significant part in his sexual development as this 
mode of dressing boys was not uncommon in 
Victorian Ireland. 9 
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After preliminary schooling , Oscar Wilde 
went to Trinity College, Dublin and thence to 
Oxford where he acquired two things: a first-
class degree-and syphilis from a local harlot 
by the name of "Old Jess." The resultant 
mercury therapy left him with blackened, cari-
ous teeth for the rest of his life. From Oxford he 
went to London, where his flamboyant dress 
and brilliant conversation brought him notori-
ety, soon enhanced by a more solid reputation 
as an author of plays, prose, and poetry. 
In January 1882, Wilde came to North 
America, landing in New York where he was be-
sieged by a curious public and press . When 
asked by customs officials if he had anything to 
declare , he said, "Only my genius ." He 
reached Richmond on 11 July , notice of his lec-
ture appearing for the first time in the Richmond 
Whig on 28 June 1882, and announcing that 
tickets priced at $1 . 00 for seats in the dress 
circle and front stalls and 50¢ elsewhere were 
available from Ramos and Moses. 
The report of the lecture in the Daily Dis-
patch of 12 July 1882, under the headline, 
" HOW THE GREAT APOSTLE OF AESTHETIC-
ISM LOOKED," is devoted more to Wilde 's 
dress than to his words: " Mr Wilde was dressed 
in the oft-described silk small clothes , including 
knee-breeches, &t. , silk velvet surtout, old style , 
satin-lined . There was pending from his neck a 
long array of white dimity corrugated into nu-
merous ruffles and extending some distance 
down the diaphragm. Mr. Wilde 's appearance 
was greeted with slight applause . . . . His hair, 
which was of brown texture , was parted in the 
middle and worn in ringlets over ample shoul-
ders suggesting Buffalo Bill , only the aesthete is 
by no means so comely a specimen of man-
hood as the great Indian scout and prairie war-
rior." 
The critic continued by noting , ''An allu-
sion to beautiful women and their influence was 
recognized ... as having a personal application 
to that section of the fair sex present , and was 
received with vociferous acclaim .'' 
On his return to England , Wilde continued 
his career as a brilliant writer and critic , meeting 
the cream of aristocratic London , including 
James McNeill Whistler , the American ex-
patriate painter . 10 Whistler 's reputation as a 
conversationalist equaled Wilde's, and they be-
came great friends . Wilde , however, extended 
his criticism to art, and this enraged Whistler 
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who , with some justification , considered that 
Wilde's knowledge of painting did not qualify 
him as an art critic. Their open hostility led to 
the famous story of how Wilde, on hearing 
Whistler make some particularly witty remark, 
said, "Jimmy, I wish I'd said that." Whistler re-
plied, " You will , Oscar, you will ." 
The Gay 90s 
In 1891 , Oscar Wilde , at the height of his 
career, met Lord Alfred Douglas, son of the 
Eighth Marquess of Queensberry . The 
Marquess, familiarly known as " Q," is best 
known for the Marquess of Queensberry's 
Rules, which brought some decorum into the 
prize ring of the day and remain the basis of 
modern boxing refereeing. 11 Oscar and Lord Al-
fred , or "Bosie" as he was known , soon be-
came close friends to the disgust of "Q," who 
was better known as a bullying sportsman than 
as a doting father . The Queensberrys were no-
torious for their sexual escapades , particularly 
" Old Q," the Fourth Marquess, who , in his 
eighties, erected a bow window in Piccadilly so 
that he could ogle passing girls . 
This family failing , however, did not lead 
to " Q's" accepting Wilde 's advances to Lord 
Alfred , and the Marquess, with one of his prize 
fighters , went to Wilde 's house to order him to 
leave his son alone. After some angry words, 
Wilde showed " Q" to the door, telling his ser-
vant that he was never to admit this " most infa-
mous brute in London " to his house again . 
Queensberry, in a frenzy , planned to ruin the 
first night of Wilde's play, The Importance of 
Being Earnest, but was prevented from entering 
the theatre by a cordon of police, thoughtfully 
recruited by Wilde . 
Frustrated, "Q" stormed into the Alber-
marle Club and gave his card to the hall porter 
with instructions that it be handed to Wilde 
when he next came in; on the back of the card 
was written , "For Oscar Wilde posing as som-
domite. '' The usual explanation of the incorrect 
spelling is that the enraged ''Q'' misspelt 
"sodomite," but perhaps spelling was not his 
strong point . Wilde received the card about two 
weeks later and unwisely sued the Marquess of 
Queensberry for criminal libel. 
The trial attracted the greatest legal minds 
of the day, and by brutal cross examination , 
" Q's" counsel showed that the libelous state-
ment was almost certainly true. Wilde 's defend-
ing counsel declared his intention to withdraw 
from the case, first in private to Wilde, and the 
next day in court. The Marquess was immedi-
ately acquitted, and his lawyers referred the evi-
dence adduced at the trial to the Director of 
Public Prosecutions. 
Wilde left the court at noon on the fifth of 
April, 1895 and was arrested at 6:30 PM that 
evening. There is no doubt that he could have 
fled the country, and was indeed advised to do 
so, but he vacillated helplessly, and the last 
train for the continent left without him. At his 
trial , the jury could not agree on a verdict, but 
on retrial, he was convicted of committing "acts 
of gross indecency '' and sentenced to two 
years hard labour. In passing sentence, Mr Jus-
tice Wills said that it was the worst case he had 
ever tried , accused Oscar Wilde of being " the 
centre of a circle of extensive corruption of the 
most hideous kind ," and added that he was 
"expected to pass the severest sentence that 
the law allows'' although it was ''totally in-
adequate for such a case as this." 12 
Broken in spirit and health upon leaving 
prison, Wilde went to France and died there in 
1900. The cause of his death has been attrib-
uted to neurosyphilis or to an intracranial suppu-
ration from otitis media. He had sustained an 
ear injury in prison with subsequent and recur-
rent drainage. 13 His bones were reinterred in the 
famous Pere-Lachaise Cemetery in Paris in 
1909. 
In 1912, Jacob Epstein, then an avant-
garde sculptor, was commissioned to create a 
suitable tombstone for Oscar Wilde; his re-
sponse was to hew an immense winged sphinx 
from a 20-ton block of Hopton Wood stone. 
This was transported to Paris and placed 
over Wilde's grave, but the nakedness of the 
sphinx's genitals was considered indecent by 
the Paris gendarmerie, who refused to let Ep-
stein complete his work. 14 There is a story, per-
haps apocryphal, that two English ladies were 
so incensed by the tombstone's offending or-
gans that they stoned them, some of the chips 
ending up in the cemetery office as pa-
perweights! 
Oscar Wilde was bisexual, and his mar-
riage in 1 884 was followed by the birth of two 
sons within two years. No satisfactory ex-
planation of his deviation has been given~ and 
theories still abound to explain it, as indeed they 
do for all homosexuality. Suffice it to say that in 
the 1 890s-the decade of " decadence"-li-
cence of all kinds was condoned by the follow-
ers of aestheticism, and Wilde, who was no 
drinker or drug taker, suffered the penalty of 
being branded with the most heinous offence of 
all in Victorian eyes. Had he ignored Oueens-
berry's action, he might well have continued his 
career in peace, as did many of his " decadent" 
colleagues, despite their excesses. 
That Oscar Wilde has been forgiven by 
society became evident in 1954, the centenary 
of his birth , when the London County Council 
unveiled a plaque affixed to the wall of the 
house he occupied at the time of his trials. 
Appropriately, the ceremony was conducted 
by Sir Compton Mackenzie, the flamboyant au-
thor, who once said , " All my life I've lived hand 
to mouth. Damned good hand to mouth, mind 
you .,, 15 
What is to be learned from repeating the 
tale of Oscar Wilde? Perhaps only that the un-
usually harsh penalties imposed on homosexu-
als must now be redressed by an enlightened 
humanity. Today, consenting homosexuals may 
live together openly in Britain; in this country , 
prosecutions of homosexual offenders have be-
come rare , and as a recent Time essay said , " It 
is true that America has a great deal to be 
ashamed of in its treatment of homosexual citi-
zens .... The best public policy toward homo-
sexuals is no policy at all-no sodomy laws, no 
special interventions pro or con. On matters of 
consensual adult sex, the law is, or should be, 
blind. '' 16 
The words that Oscar Wilde wrote to Lord 
Alfred Douglas from Reading Gaol could today 
well apply to the world: " Perhaps I am chosen 
to teach you something much more wonderful , 
the meaning of Sorrow, and its beauty." 11 
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Medicine in Retrospect 
[The following is a transcript of an informal talk 
by Ors Kinloch Nelson and Charles M. Cara-
vati, presented in 1974 to the School of Medi-
cine of the Medical College of Virginia, Health 
Sciences Division of Virginia Commonwealth 
University, Richmond, Virginia.] 
Dr Caravati: 
One of my first recollections while I was a 
medical student was the severe pandemic of in-
fluenza of 1 91 8 and 1 91 9. There were in ex-
cess of a thousand patients at one time in the 
John Marshall High School, which was used as 
an emergency hospital. The death rate waster-
rifically high; the most serious complication was 
empyema, but most of the deaths were appar-
ently caused by betahemolytic streptococcus 
infection superimposed upon the influenza 
pneumonitis. The medical students acted as 
orderlies in the temporary hospital. 
If you went on the wards of St Phillips or 
Memorial Hospital in those days, you would find 
any number of cases of typhoid fever between 
July and September; there was no therapy for it, 
and in many patients it was fatal . Malaria was 
common until the end of August. As people 
went to the seashore, many of them developed 
malaria. 
In the winters, pneumococcal pneumonia 
was a very common disease. All we really knew 
about it was how to diagnose it. There was 
nothing we could do for it except [to take] gen-
eral measures and to comfort the family and · 
have a good nurse on the job. It is interesting to 
recall that during the influenza epidemic, the 
Richmond Health Department stated the only 
worthwhile medicine was whiskey. 
In 1934 a type specific serum came into 
use, which was very effective for certain specific 
types of pneumococcus. The health department 
had /a typing station where we could have the 
sputum typed promptly, but the severe reac-
tions encountered [by the patients] kept a lot of 
physicians from using it because of its potential 
anaphylactic effect. 
Childhood diseases were serious and 
prevalent. The most fatal in those days was la-
ryngeal diphtheria, and some of us were trained 
to intubate for this complication . Interestingly 
enough, laryngologists never did it. Dr Lip-
scomb, a general practitioner, was an expert in-
tubator. He saved many lives by using laryngeal 
tubes. 
There were very few drugs that were of 
any real help, although some newer ones were 
being developed and used. For instance, Sal-
varsan and. bismuth were being used for syphi-
lis. At that time, too, we were beginning to real-
ize that specific vitamins helped some ·of the 
disorders we were seeing , particularly those in 
children . 
When I was a freshman medical student, 
Dr Joseph Goldberger of the Public Health Serv-
ice came and talked to the profession about 
pellagra and explained that a good general diet 
and nicotinic acid would cure it. I remember 
very well his making the statement that more 
than 300 people had died of pellagra that year. 
Then came one of the great break-
throughs in medicine--the discovery of insulin 
by Banting and Best in Toronto j n 1922. This 
was the first time, I believe, that a cooperative 
therapeutic effort was made by the medical pro-
fession and a pharmaceutical manufacturer. Eli 
Lilly co-produced the insulin for Banting and 
Best, which was later distributed to doctors in 
designated regions of the country by a physi-
cian in each region , who had to be provided 
with the proper protocol for its use. 
In Richmond we had to apply for insulin to 
Dr Lester Newman, a pathologist in Washing-
ton , DC. I had come back to Richmond in 1924 
to practice, and I had been here only a few 
months when I went to Sheltering Arms Hospital 
and saw a four-year old child in diabetic coma. 
It was the second episode of coma she had 
had, and I remember speaking to Dr Newman 
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on the telephone and trying to persuade him to 
send me insulin without a protocol. 
Eventually he agreed and sent some on 
the RF&P Railroad , and the drug was given to 
this child the next day. Later, when she was 
about 30 years of age, she walked into my of-
fice one day just to say hello and tell me she 
was living in Cleveland. That was the first real 
success in controlling chronic disease that I can 
recall, and I think it is significant to remember 
the way it was handled by the profession and 
pharmaceutical industry. 
In 1925 Minot and Murphy discovered 
that people with pernicious anemia improved on 
an adequate diet, particularly one with flesh 
meat and liver. Practically every patient treated 
in this way went into remission and stayed in re-
mission indefinitely if they were kept on this 
treatment . I think the original work was done in 
the latter part of 1925, but we didn 't use it clini-
cally until 1926 and 1927. 
I recall one female with pernicious 
anemia, who had been kept alive with frequent 
transfusions, and the dietician in the hospital 
ground up some pork liver and started feeding 
the patient half a pound a day. She went into re-
mission shortly after receiving this new diet and 
died of a cerebral accident eight years later. It 
was soon discovered that the active principle in 
eliminating the anemia was in liver. 
Dr William Branch Porter, chairman of the 
Department of Medicine at MCV, had the Valen-
tine Company of Richmond manufacture an ex-
tract from liver, and the company made the first 
extract that was for sale in America. It was 
called Valentine Extract E-29, and it was a very 
effective treatment. It took about one ounce of 
the oral extract each day to control the anemia. 
The rest of the story, as you know, was the dis-
covery of B-1 2 as the active principle. 
Not long after this we found out that bru-
cella abortus and tularemia, which were origi-
nally thought to be diseases in animals, could 
cause human disease, and we began to diag-
nose a few cases in this area, though frankly 
there were very few cases in Richmond or even 
in Virginia. 
Endocrinology was beginning to be talked 
about at this time, and the active principle of the 
parathyroid gland was isolated. Between 1932 
and 1934 Barr, who was professor of medicine 
at Barnes in St Louis, and later at Cornell, de-
scribed the clinical symptoms of hyper-
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parathyroidism and how it could be cured by 
the removal of the adenoma in the parathyroid 
gland. He showed that after surgery the cystic 
changes in the bones went away, and the bio-
chemical changes all went back to normal. This 
work led to the treatment of certain cases of hy-
poglycemia by the removal of a pancreatic ade-
noma. 
In 1 93 7 ergotamine-tartrate was reported 
by Lennox as effective treatment for migraine 
headaches, and we thought this was a great 
thing because previously there was nothing a 
physician could do for these people except put 
them to bed , pull down the shade, and let them 
stay there, nauseated and vomiting , for three or 
four days. 
In Germany in 1 935, Domagk found that 
certain sulfonamides were very effective against 
betahemolytic streptococcal infections. In this 
country in 1936, it was recognized by the pro-
fession as a powerful anti-infectious agent. 
The first drug was called Prontosil , a sul-
phanilamide that came in the form of a red half-
gram tablet. With the possible exception of 
quinine for malaria and of Salvarsan , which was 
used for the treatment of syphilis, this sulpha-
. nilamide was the only specific drug used to treat 
infections. 
I remember seeing a 36-year old man with 
a temperature of 104° or 105 ° F with a mem-
brane in his throat and cervical lymphadenopa-
thy and betahemolytic streptoccus infection of 
his throat, which two days later became a 
bloodstream infection. At that time Prontosil had 
just been developed, and it was given to this 
man who had difficulty in swallowing the first 
couple of tablets. 
He stayed sick for another two days, but 
in 48 hours his temperature began to come 
down, his tachycardia disappeared, and he was 
considerably better in five to seven days. In 
those days we didn't repeat blood cultures, but 
clinically he became well. After that, Sulpha-
thiazole , Sulphadiazine, and Sulphapyridine 
came into use, Sulphapyridine being an ex-
cellent drug for pneumococcal pneumonia. 
Though penicillin was discovered by 
Fleming in 1929 and subsequently purified by 
Florey and Chain in Oxford, it was translated 
into clinical usefulness by scientists at the North 
Regional Laboratories in Peoria, Illinois. Pen-
icillin was made available during World War II, 
and its distribution was directed by Dr Chester 
Keefer of Boston. In the beginning it was used 
only for gram-positive infections. 
Or Nelson: 
What I am going to say is somewhat auto-
biographical. I came back here [to Richmond] 
to practice medicine at the McGuire Clinic on 
July 1, 1929, at a salary of $150 a month. In 
October, 1929, the roof fell in! St Luke's Hospi-
tal usually had 85 to 90 patients. The cut-off 
point was around 65 or 66, as I understood it; 
at that level you came out about even . Anything 
above that was nice, but anything below that 
was real tough . 
The hospital population dropped off al-
most immediately to around 20 where it stayed 
for several years . Through the kindness of Dr 
Stuart McGuire, the institution held together, 
and my salary was gradually reduced to 
$112 .50 a month. I never knew why I got the 
50¢, but I never asked anyone. 
Mr Roosevelt came into office and started 
the WPA and the CWA and those other federal 
agencies that created work , one result of which 
was the building of the Lee Bridge. The number 
of physicians applying for the opportunity to ex-
amine the workmen who would build the Lee 
Bridge was out of this world . The man respon-
sible for these funds was Dr Wyndham Blanton, 
Sr, the present Dr Wyndham Blanton's father, 
who was recognized for his general overall in-
tegrity, so he was given the task of deciding 
who would examine these birds! 
Well, I was one of the early applicants, 
and it was finally decided that we would each 
work a certain number of shifts. We examined 
the workmen at the rate of 50¢ apiece. We 
could examine ohe man in fifteen minutes ' 
across the street from here in the basement of 
the City Hall Annex, which was recently pulled 
down. 
Shortly before this, the physicians of this 
area began to realize that the best possible ar-
rangement they could have was to work in 
groups. I think the McGuire Clinic group was 
one of the first to organize, and there was some 
criticism of this because doctors thought they 
should stand on their own feet and not associ-
ate with a group. This ied to the question of 
whether a patient could "get a square deal" in 
a group. It seemed to me then and now, that 
there is no better doctor /patient relationship 
than that in which the patient picks out his doc-
tor for whatever reason . 
There was one lady who was going to a 
doctor whose capacity was certainly rather in-
different. I asked her why in the world she 
picked out this fellow. She said he looked more 
like a bulldog than any other doctor she 'd ever 
seen. Well, on this basis he had her confidence, 
so she 'd tell him her problems, which he at-
tempted to take care of . She expected to pay, 
and he expected her to pay, and you can 't beat 
that . In my opihion there isn 't any other system 
that will ever equal that , but we have to play it 
the way it is. 
There was interest about that time in the 
care of the indigent of the City of Richmond, 
and Dr B. Foster of the Health Department sug-
gested that I take on the job as doctor to the 
poorhouse. To tell you the truth, I didn't exactly 
know where the poorhouse was, but I ended up 
there working part time at $50 a month . Added 
to the $112 .50 [I was already making at 
McGuire Clinic] , this was a considerable in-
crease, and things seemed to be getting better. 
There used to be an idea that the physi-
cian had a certain responsibility to the poor. 
Some physicians had office hours at certain 
ti'mes of the week for those who could not pay 
in the same office in which, at other times, they 
saw those who could pay. 
We seem to have shifted away from that 
feeling of taking care of the overal.1 population . It 
has somehow become the responsibility of 
somebody else to take care of those who can-
not pay. It is interesting to remember that there 
once seemed to be a shortage of patients. A 
group opened an office with the idea of helping 
out in an indigent area. Shortly, the patients 
didn 't seem to be there, and they had to ciose 
down. This was an odd circumstance. 
After the second World War, I think the 
most Striking thing that took place was the de-
velopment of the "medical center. " The medi-
cal school had, of course, been well known for 
many years , and everyone knew something 
about the teaching of medical students and to 
some degree [had knowledge of] the housestaff 
and nurses. 
There was the necessity for employing 
faculty members to take care of many obliga-
tions besides direct patient care and teaching 
residents and students. This was hard to get 
across to people. All of these concerns have 
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brought about full-time physicians who, in many 
instances, have never really practiced medi-
cine-have never really gotten down to the nitty 
gritty. This makes it difficult for them to under-
stand the problems of the practice of medicine , 
and, on the contrary, those in practice have dif-
ficulty in understanding the problems of the fac-
ulty members who are in ''the ivory tower .' ' 
These divisions have led to a lot of prob-
lems, but they are not new. If you go back in the 
history of the Medical College, you will find 
some of the most remarkable fights you ever 
saw in your life _!hat_ took place before the 
1900s. In the meantime, it appeared to me 
that the medical student and housestaff mem-
ber were somehow divorced from the practice 
of medicine and consequently were not "inter-
ested " in practicing medicine . Now, this is ba-
loney because the statistics show something 
like 90-odd percent of the graduates of this 
school have gone on to practice medicine. 
Back in 1950, Dr Sanger managed to get 
some money to allow us to rotate our house-
staff through community hospitals, and we sent 
them to four or five-I think Eastern Shore, 
Franklin , Farmville, Fredericksburg, and Nor-
folk , but this created some problems. These 
boys were, for the most part, married , which , as 
you know, is one of the greatest changes to 
take place in medical education . 
When I was a student, nobody was married. 
There was one fellow who was married-in-
cidentally, his wife had a baby, which was the 
biggest surprise all of us ever had. We were 
senior medical students and saw this lady · 
everyday, and if you had asked me the day be-
fore she had the baby whether she was preg-
nant or not, I would have said no. 
In any case , through Dr Sanger 's influ-
ence we began to try introducing the housestaff 
and students to some of the actual practice situ-
ations that exist in this neighborhood. After 
rotating the interns through the hospitals, we 
started a Home Care program, for which we ob-
tained money through the Commonwealth 
Fund . The idea was for medical students to see 
something that took place in actual life . 
Unfortunately, this was not exactly actual 
life. This was life of a sort , but many physicians 
today never see patients such as those that 
were seen in Home Care then . These were 
people who lived in half a barrel over here on 
the city dump and had no money and no any-
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thing. How they ate, lived or whatever, nobody 
knew. You don 't see patients like that in your 
practice-at least, I hope you don 't. Then we 
put students out in the affiliated hospitals, very 
much the same hospitals as we sent the interns 
to 20 years ago , plus a few more. 
There are a couple of other things that 
stand out in my mind as developments over the 
years . I remember one difference is that now if 
you call a doctor, sometimes nobody answers 
the telephone. This seems remarkable . If you 
called a doctor in 1930, about four people 
would answer the phone. Even today a ringing 
telephone gives me the jitters because I'm not 
sure whether it is somebody who really needs 
something or somebody that I need. I cannot 
imagine how it is possible to practice medicine 
and have an office that [allows telephone calls 
to go unanswered], but it can be done, and it is. 
The second thing that bothers me is the 
idea of telling everybody everything. I was 
raised on the principle that the doctor knew 
best, and the patient didn 't know anything , and 
the better off he would be if he didn 't know any 
more. I am not sure but what this is right . I think 
this business of advising everybody of all the 
details of all the problems that they have or may 
have is really bad . I don 't know what you do 
about it exactly, but I can tell you what I have 
done about it. 
I was called one night to see a man who 
had , as far as I could see, a coronary throm-
bosis. So I went back to the office and got the 
electrocardiogram machine which took three 
leads-three, not twenty-three-and went 
back to his house. According to the three leads 
that ran out of the thing , it looked to me like he 
had a coronary thrombosis. So I told him I had 
to go back to the office to develop the film. 
Well , this didn 't make much sense as it 
was coming right out of the machine, but it 
suited him all right , so I went back and devel-
oped the film , and while I was there I got a nor-
mal electrocardiogram. I went back [to his 
house] , and he said, " How does that thing 
look?" I said , " Boy, it looks fine to me. Here it 
is . You want to see it?" He said, " Well , I don 't 
know anything about those things," and I said , 
" That doesn't make any difference. I' ll show it 
to you. " 
So I pointed out the normal pulse waves 
and ORST, and he started feeling better right 
away. I didn 't do him any harm, I think , and 
1 don 't see what good it would have done 
for me to tell him how it did look by saying, 
"Boy, you've got it!" Now, I do think you ought 
to tell the patient 's wife or son or whoever is re-
sponsible. 
Another thing that interests me is that I be-
lieve the AMA or somebody has decided that 
we are short 50,000 doctors. I don't know how 
they arrived at that figure ; there's some com-
plicated calculation which shows that if you 
graduate all the doctors who are graduating, 
and al l those who have died or are dying, and 
none die un~xpectedly or in an epidemic, in 
some unknown year in the future we will reach 
the necessary number of doctors, whatever that 
means. I think that 's " for the birds." 
I think that in your lifetime, and hopefully 
mine, we will have doctors coming out of our 
ears. By the time the doctors now being gradu-
ated by medical schools, plus those who will 
shortly begin to do so, plus the trained person-
nel now going on in various thing$ like physi-
cians' assistants, nurse practitioners, med-x , 
and so forth , we will have an excess of people 
doing first-line medical care . It is a supply and 
demand business, and I hope I live to see that. 
Discussion 
Question : Who is the greatest medical character 
you remember in Richmond? 
Dr Nelson : 
I can think of one doctor I won 't name 
who was always referred to as the '' cheerful 
little cricket." To my knowledge he never 
smiled in his life. Oddly enough , his patients 
seemed to love this very sad approach ; every-
thing was going downhill all the time, but he had 
plenty of practice-plenty. 
I recall another who was a great crier. In 
other words, if anybody was very ill or some-
body died , and members of the family were 
weeping, he was the greatest weeper there. 
Tears ran down his cheeks like a waterfall. He 
was very popular . 
Dr Caravati : 
Dr W. T. Oppenheimer was one of the real 
interesting medical personages of his time. He 
was President of the Richmond Academy of 
Medicine in 1900, and he lived about 45 more 
years . He was an excellent general practitioner , 
if you want to use that term, and he did general 
surgery. As far as we know, he did it well. He 
was the best toastmaster in the area, and every 
medical meeting was enlivened by him . He 
would always tell a story, and he always had 
dozens of them. 
Question : Dr Nelson, how about your service in 
the 45th? 
Or Nelson: 
Well , I'm glad you mentioned that. I went 
into the 45th General Hospital as a major. Why I 
wasn 't made a higher rank I ni:.iver could under-
stand . Dr Thompson, I believe, was a lieuten-
ant , and in no time at all he became a captain , 
but I was still a major. Shortly after that, he be-
came a major; I was still a major. Shortly after 
that, I left the army. I figured I'd done all I could. 
I couldn 't get promoted, so forget it . What Dr 
Thompson is talking about is that I became ill 
due to my arduous service and was sent home 
on a stretcher. As I embarked at Naples, the 
band came down to see all the poor souls who 
were going home, and among them were 16 
pregnant nurses. 
One of them had just had a baby--cutest 
baby you ever saw. One nurse had arthritis, and 
she had a lot of x-rays so nobody would accuse 
her of the problem that the other girls had . 
Incidentally, this was the first boat from 
Naples that came straight back to the States. 
Prior to this time, wounded and sick troops were 
sent from Naples to Africa. Sometimes the doc-
tor in Africa was kind of an eager beaver and 
wanted everybody to serve, so he'd send them 
back to the front in Naples. Well, they didn't like 
that , so they worked out a boat to take them 
straight back to the States. 
The chief doctor on this boat was an ob-
stetrician, and he had been in the army for I 
don't know how long. He hadn't seen a preg-
nant lady since he got into the army, and we 
presented him with 16 cases. He nearly had a 
fit; he was examining people all the way home. 
Dr Caravati: 
I thought it might be worthwhile just com-
menting that during World War I many of you 
may not know the Medical College of Virginia 
was also the 45th General Hospital under [the 
direction of] Dr Stuart McGuire, and Dr Nelson's 
father was one of the prominent members of the 
staff in 1918. The hospital was in action during 
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the period of some of the hardest fighting 
around the Argonne. The history was written by 
Dr Joseph Geisinger, who was a uroloQist in 
town, and it is well worth reading . 
Question: Will you comment on the merger of 
the two school~ of medicine in Richmond? 
Or Caravati: 
You'll have to remember that geographi-
cally the two schools were only two city blocks 
apart which, of course, should have never 
been. All the faculty were part time, and the fac-
ulty members in the · two schools practically 
never spoke to each other. They had very 
strong feelings about this, but perhaps the com-
petition made for good medicine because they 
tried to outdo each other when they made sci-
entific presentations. 
In 1 91 O the Flexner Commission found 
that they were gradufiting too many physicians 
in the $late and recommended the merger of 
the Medical College of Virginia and the Univer-
sity Coll~ge bf Medicine. After that, there was a 
fight about twice a week, as I understand it. 
However, the merger was accomplished in 
1 91 3 through the efforts of many outstanding 
people led by Dr Stuart McGuire, Dr George . 
Ben Johnston, Dr Christopher Tompkins, and 
Mr Eppa Hunton. Ors McGuire and Johnston 
were not friends; only as far as their interest in 
medical education did they get together. 
There were a lot of stories about individual 
physicians and their behavior at meetings. Dr 
Daniel Coleman is said to have come to a 
meeting with a pistol on his hip, and no one 
knew whether he had real bullets in it or not. 
He stood on a chair and said, "I am not as big 
as the rest of you, but look here." 
Or Nelson: 
The father of Mr Eppa Hunton was really 
the catalyst between the warring groups and 
brought them together in the consolidation of 
the Medical College of Virginia in 1 91 3 more 
than anyone else. 
Question: Do you have any further comments 
about the care of the indigent patient? 
Dr Caravati: 
Well, one dramatic example is Sheltering 
Arms Hospital. Sheltering Arms was for years 
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right over here on Clay Street. Now it is adjacent 
to Richmond Memorial Hospital. In days gone 
by, every doctor thought it a privilege to be able 
to take care of patients at Sheltering Arms. I 
know we all thought it was a great thing to be on 
the visiting service, and also to teach the 
nurses; we really did think it was a privilege to 
do all thi~ . No doctor ever received a penny for 
his services, nor did any patient pay for his or 
her care. 
Question: Have you s~en anything in medical 
education that has changed, ot is educating doc-
tors about the same as when you were in 
school? 
Dr Nelson: 
Everything has changed. I was thinking 
the other day about Dr W. B. Porter. Dr Porter 
was a very handsome person, and he was very 
concerned about his appearance; he always 
had on a spotless white coat and a little flower 
in his buttonhole. He had the idea that he ought . 
to look like a doctor-whatever that means. 
Were he to see some of our present campus 
candidates, I'm sure he'd be revolving wherever 
he is. 
The most remarkable change I have seen 
has been in the last four or five years. Everyone 
seems to be going into primary medical care, 
which I think is a very sall.jtary move. It's hard 
for me to tell, you see, because I was raised as 
a doctor. My earliest recollection is over here in 
the old Memorial Hospital with my father, sitting 
in the waiting room while he went to see a pa-
tient or two. I can remember the horse he had 
named Phyllis. Every now and then Phyllis 
would take it into her head to go home. When 
we would come out of wherever we were, there 
was no horse. 
Dr Caravati: 
One development that has been inter-
esting to me is that now you can't find a doctor 
to come to your home. Most patients can be 
transported to an emergency room in one of the 
hospitals. Probably 50 percent of the patients 
seen there are not true emergencies. Because 
of well qualified physicians who are full time, 
good care is administered in an excellent set-
ting. This makes many house calls unneces-
sary, and I believe this practice will grow rap-
idly. To me it is a really interesting evolution of 
the practice of medicine, and I think it is going 
to continue to grow. 
Or Nelson: 
I would like to put in a plug for house calls. 
If you have an occasion in your practice to see a 
patient in the home, I would recommend it. 
There is no better place you can get to know 
them as well , and it has always struck me as 
odd that when you get into the home, about the 
only private spot is the bathroom. If you want to 
talk to the wife about the husband, you just call 
her into the bathroom and shut the door, and 
nobody else will come in there. 
Or Spencer: 
Thank you very much indeed, Dr Nelson 
and Dr Caravati. You have shown that history 
doesn 't have to be dull and uninteresting, and I 
am delighted that you could tell us about your 
50 years of practice. Thank you very much 
again . 
Or. Nelson is Dean Emeritus and Dr. Caravati, Professor of Medicine Emeritus. Medical College of 
Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia. 
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Recent Advances in Cancer Chemotherapy 
ROBERT B. DIASIO, MD 
Associate Professor of Medicine and Pharmacology, Medical College of Virginia, Health Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
The present status of cancer chemother-
apy can be reviewed in light of selected basic 
principles with an acknowledgement of the role 
of established chemotherapeutic agents. Four 
chemotherapeutic agents recently approved for 
clinical use and their impact when used in com-
bination regimens should be examined . Several 
important concepts influencing chemotherapy 
in the 1980s include the use of chemotherapy 
in the adjuvant setting, the use of hormonal re-
ceptor data in planning therapy, and the use of 
in vitro tests on tumor specimens to predict tu-
mor sensitivity to cancer chemotherapy drugs 
(prior to administration of these potentially toxic 
drugs to a particular patient) . Lastly the reader is 
cautioned about the potential of long-term com-
plications with certain chemotherapy agents, 
especially in those patients who have had com-
plete or extended partial remissions. 
Review 
The modern era of cancer chemotherapy 
began approximately 40 years ago when nitro-
gen mustard , a derivative of the mustard gases 
used in the World Wars, was demonstrated to 
cause regression of lymphomatous tumors ini-
tially in studies involving mice and later man. 
Since that time a variety of chemicals and natu-
ral products have been synthesized (or isolated) 
and subjected to various screening programs in 
an attempt to identify potential clinically-effec-
tive drugs. Today there are approximately 30 
drugs that have been approved and deemed 
valuable in the treatment of various human can-
cers. 1 These agents can be categorized into six 
major classes (Table 1 ). 
The development of these diverse agents 
which effect various critical biochemical steps 
or processes has occurred during a period in 
which there have been rapid and significant 
gains in our understanding of the molecular bi-
ology of the cell. Concomitantly , there has been 
an increased understanding of tumor cell biol-
ogy which has markedly influenced the way 
cancer chemotherapy drugs are used today. 
Cell kinetic studies in animal models have dem-
onstrated that a single malignant cell can multi-
ply within a host animal to eventually kill the 
host . Thus curative therapeutic approaches 
must aim to eradicate every malignant cell . 
Studies with anticancer agents in animal models 
have shown that chemotherapy kills cells in a 
first-order kinetic manner, ie , with each treat-
ment a constant percentage (rather than a con-
stant number) of cells is killed . These generally 
accepted "principles" have provided support 
for the aggressiveness now used in many of the 
multiagent chemotherapy regimens and have 
formed the basis for adjuvant and maintenance 
chemotherapy. 2 
Multiagent , or combination chemother-
apy, the major approach used in advanced can-
cer today, has been influenced by a better com-
prehension of the cell cycle . Thus it is 
recognized that certain drugs act on cells only 
in a specific phase of the cell cycle (the life 
cycle through which a cell passes from its origin 
when formed from the mother cell to the point at 
which it in turn divides into daughter cells) while 
other drugs are non-cycle specific, being able 
to affect cells regardless of where they are in 
the cell cycle, including cells not actively repli-
cating . The recognition of this concept has 
been utilized in designing effective combination 
regimens which aim at affecting cells in different 
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TABLE 1 
Classification of Cancer Chemotherapy Agents 
phases of the cell cycle to obtain the maximum 
therapeutic effect. 
Alkylating Agents 
Mechlorethamine (Mustargen) 
Cyclophosphamide (Cytoxan) 
Chlorambucil (Leukeran) 
Melphalan (Alkeran) 
Triethylenethiophosphoramide (thiotepa) 
Nitrosoureas 
(BCNU or Carmustine) 
(CCNU or Lomustine) 
(5-(3 ,3-Dimethyl-1-triazene)-imidazole-4-
carboxam ide) 
(Dacarbazine or DTIC) 
Anti metabolites 
Methotrexate 
5-Fluorouracil (Fluorouracil , Adrucil) 
Cytosine arabinoside (ara-C or cytosar) 
6-mercaptopurine (Purinethol) 
6-thioguanine (thioguanine) 
Antibiotic 
Dactiomycin (actinomycin D. (Cosmergen)) 
Mithromycin (Mithracin) 
Doxorubicin (Adriamycin) 
Daunorubicin (Daunomycin) 
Mitomycin C (Mutamycin) 
Bleomycin (Blenoxane) 
Natural Products 
Vinblastine (Velban) 
Vincristine (Oncovin) 
L-Asparaginase (E.lspar) 
Miscellaneous Agents 
o,p '-DDD (Mitotane (Lysodren)) 
Hydroxyurea (Hydrea) 
Procarbazine (Matulane) 
The success of chemotherapy in the man-
agement of human cancer can be seen in Ta-
bles 2 and 3. 2 Table 2 demonstrates that in at 
least seven tumor types, chemotherapy now of-
fers either cure or at the very least a significant 
prolongation of life. While actual cure has not 
been achievable for the five tumors listed in 
Table 3, there nevertheless has been a demon-
strated increased survival and palliation. For the 
remaining tumor types not listed, including the 
relatively frequent cancers such as carcinoma 
of the lung and large bowel , cure and palliation 
are less likely at present. With the development 
of new agents, it is hoped that more effective 
combination regimens will be created to im-
prove survival in these currently less responsive 
tumors as well. 
Update 
Over the past several years there have 
been four new agents introduced clinically that 
are now not only approved for non-investiga-
tional use but also occupy important roles in 
cancer chemotherapy already. The increasing 
use of all four drugs necessitates a basic under-
standing of them by every physician participat-
ing in the care of a particular cancer patient. 
Cis-platinum diamine dichloride (Cisplatin, Platinol) Doxorublcln (Adrlamycln} 
Hormones 
Estrogens 
Androgens 
Progestational Steroids 
Adrenal Steroids 
Antiestrogen tamoxifen citrate (Nolvadex) 
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Fig. I. 
Perhaps the most important new agent is 
Adriamycin . This drug and the closely related 
drug Daunorubicin (Daunomycin) are anthracy-
clene derivatives obtained as fermentation 
products from Streptomyces (Fig 1 ). These 
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TABLE 2 
Cure or Increased Survival 
Type of Cancer 
Gestational trophoblastic tumors 
Chemotherapy 
Methotrexate , dactinomycin, 
Results 
70% cured 
vinblastine 
Burkitt 's tumor 
Testicular tumors (nonseminoma) 
Cyclophosphamide (many others) 
Dactinomycin, 
50% cured 
70-80% respond; 2-3% cured 
Methotrexate chlorambucil, 
Bleomycin , Cis-platinum diamine 
dichloride 
Wilms ' tumor Dactinomycin plus vincristine with 30-40% cured 
surgery and radiotherapy 
Neuroblastoma Cyclophosphamide with surgery 5% cured 
and /or radiotherapy 
Acute lymphoblastic leukemia Daunorubicin, prednisone , vincristine, 90% remission ; 70% survive beyond 
6-mercaptopurine, Methotrexate, 5 years 
BCNU 
Hodgkin's disease, stage lllB and IV MOPP, ABVD 70% respond; 40% survive beyond 
5 years 
(Note: Adapted from I H Krakoff , Cancer Chemotherapeutic Agents , Ca-A Cancer Journal of Clinicians, 27, 1977, 132.) 
(By Permission) 
drugs are classified as antibiotic cancer chemo-
therapy agents. 
The mechanism of action of both drugs is 
believed to be via inhibition of DNA synthesis. 
These agents are known to interact with DNA, 
eventually intercalating into the nucleic acid he-
lix leading to uncoiling of the DNA and inhibiting 
both RNA and DNA synthesis. Both agents are 
maximally effective during the S phase of the 
cell cycle, but inhibition can occur at all stages 
of the cell cycle, particularly at higher concen-
trations. 3 
The pharmacology of these drugs is still 
somewhat incomplete. At present they are used 
only intravenously. The major site of metabolism 
is in the liver by both soluble and microsomal 
enzymes. Less than 1 0% of the drug is ex-
creted in the urine. Because of the importance 
of liver metabolism, the dose of Adriamycin is 
reduced in the presence of hepatic dysfunction . 
No· drug adjustments are made for renal dys-
function . The total dose should not exceed 
550-600 mg/M 2 . 2 ·3 
Both drugs have similar side effects and 
toxicities including: 1) gastrointestinal (nausea, 
vomiting, diarrhea, and stomatitis); 2) hemato-
logic (leukopenia with a nadir at 1 0-1 5 days, 
and thrombocytopenia); 3) dermatologic (alo-
pecia, local phlebitis and necrosis if extrava-
sated); 4) cardiac (by far the most serious tox-
icity with these drugs is manifested as 
congestive heart failure due to a diffuse car-
diomyopathy). 
The major indications for Daunorubicin 
(Daunomycin) have been in acute granulocytic, 
and in lymphocytic , leukemia. In contrast , 
Doxorubicin (Adriamycin) has been active not 
only in leukemia but also in bladder cancer, 
breast cancer , bronchiogenic cancer, Hodgkin 
and non-Hodgkin lymphoma , thyroid cancer 
and sarcomas in general. 
Bleomycin (Blenoxane) 
Bleomycin, also of the antibiotic class of 
chemotherapy agents isolated from Strepto-
myces, is actually a mixture of several similar 
polypeptides, each having a molecular weight 
of approximately 1500. The A2 peptide is the 
major compound present in the commercial 
preparation and is believed to be the active 
component (Fig 2). 
The mechanism of action of Bleomycin 
appears to be by scission of double-stranded 
DNA, resulting in fragmentation of DNA, in turn 
causing inhibition of DNA synthesis . This drug 
appears to block cells at the G2 /M interphase 
of the cell cycle. 
The pharmacology of this drug in vivo has 
been limited by the fact that the drug is a mix-
ture of several compounds. Following adminis-
tration, it disappears rapidly from the plasma 
with an estimated half life of 1 5-60 minutes. 
Since the dq..1g is known to be excreted primarily 
via the kidneys, the dose should be reduced in 
the presence of renal dysfunction . Bleomycin is · 
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Bleomycin A 
Fig. 2. 
degraded mainly by the action of ani-
monopeptidase which is present in tumor cells, 
liver and kidney. It is absent from the skin and 
lungs, two tissues which are particularly suscep-
tible to damage from this drug. Bleomycin is ad-
ministered either intravenously, intramuscular-
ly, or subcutaneously.2•3 
ing to fibrosis. The occurrence of toxicity need 
not be related to the cumulative dose although it 
is more frequent with a total dose greater than 
250 units/M2 or a single dose greater than 25 
units/M2 . The risk is increased particularly in in-
dividuals more than 50 years old who may have 
prior lung disease or may have previously been 
treated with radiation therapy. Pulmonary func-
tion tests have not been of value in predicting 
pulmonary toxicity. A cumulative dose of 400 
units is the accepted maximum dose. Since the 
drug is a polypeptide, a potential side effect 
with this agent is anaphylaxis. Fever and chills 
As noted above, Bleomycin toxicity in-
cludes skin toxicity (such as hyperpigmentation, 
thickening, ulceration, rash, alopecia, or nail 
changes) and pulmonary toxicity. This last se-
vere toxic finding may be present as pneumo-
nitis with dyspnea, r~les and infiltrate progress-
Type of Cancer 
Prostate carcinoma 
Breast carcinoma 
Chronic lymphocytic leukemia 
Lymphosarcoma 
Acute myeloblastic leukemia 
TABLE 3 
Palliation and Prolongation of Life 
Chemotherapy 
Estrogens, castration, cyclophos-
phamide 
Androgens, estrogens, alkylating 
agents, 5-fluorouracil, vincristine, 
prednisone, Methotrexate, 
Adriamycin 
Prednisone, alkylating agents 
Prednisone, alkylating agents 
Cytosine arabinoside and 
thioguanine 
Results 
70% respond with some prolongation 
of life 
60-80% respond with probable 
prolongation of life 
50% respond with probable prolonga-
tion of Me 
50% respond with probable 
prolongation of lifa 
65% remission with prolongation 
of life 
(Note: Adapted from IH Krakoff, Cancer Chemotherapeutic Agents, Ca-A Cancer Journal of Clinicians, 27, 1977, 132.) 
(By Permission) 
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cis-Diamminedichloroplatinum 
Fig. 3. 
occur in 20-30% of patients. The possibility of 
hypersensitivity is particularly a problem in lym-
phoma. Nausea and vomiting may also occur 
with administration of Bleomycin . One toxic 
manifestation notably absent with this chemo-
therapeutic agent is the lack of hematologic tox-
icity making this drug especially appealing for 
combination chemotherapy. 
The major indications for Bleomycin have 
been in lymphomas (Hodgkin and non-Hodg-
kin}, testicular tumors, and squamous cell carci-
noma of the head and neck. Other indications 
are less clear at this time. 
Cis-Diamminedichloroplatlnum (Cis-plati-
num, Platinol) 
This agent is a heavy metal coordination 
complex of platinum containing two ammonia 
groups and two chlorines in the Cis con-
formation (Fig 3). It is listed as a random syn-
thetic type of chemotherapeutic drug . The 
mechanism of action appears to be through in-
hibition of DNA synthesis thought to result from 
both interstrand and intrastrand crosslinks in 
DNA. It appears to be cycle non-specific. 
Cis-platinum is administered in an intra-
venous solution usually in an infusion from 1 5 
minutes to eight hours. Following administra-
tion, plasma levels of the drug show a biphasic 
pattern of decay with an initial half life of 2 5 to 
50 minutes and a terminal half life of 58 to 72 
hours. Studies of distribution have demon-
strated the greatest uptake in the excretory or-
gans, ovary, and uterus. More than 90% of the 
platinum following administration is protein 
bound. Cis-platinum is excreted mainly via the 
urine. This drug should be used with caution or 
even withheld if renal dysfunction occurs with a 
creatinine clearance of <60 ml/min . An at-
tempt has been made to minimize renal toxicity 
secondary to Cis-platinum administration by 
hydrating the patient prior to drug receipt, giving 
diuretics and infusing chemotherapy slowly. 
The renal toxicity appears to be dose re-
lated. Close follow-up of BUN, creatinine, and 
uric acid , and particularly creatinine clearance 
is advisable. Other side effects include ototoxi-
city, relatively frequent nausea and vomiting, 
leukopenia, thrombocytopenia, and anemia . 
Anaphylactic reactions have been described in 
no more than 1 % of the patients given this 
drug. Peripheral neuropathies and loss of taste 
are less common side effects. 4 This drug ap-
pears to be active in testicular tumors, ovarian 
cancer, bladder cancer, and head and neck 
cancer. 
Tamoxifen Citrate (Nolvadex) 
Tamoxifen is a synthetic non-steroidal trip-
henylethylene derivative that has been demon-
strated to have potent anti-estrogen activity in 
several mammalian species. It is classified as a 
hormonal type of chemotherapy agent (Fig 4 ). 
The mechanism of action appears to involve in-
hibition of estrogen binding to cyctoplasmic es-
trogen receptors present in sensitive cells such 
as breast cancer. It is believed that following 
binding to the receptor, estradiol-estrogen re-
ceptor formation is blocked. Since. this receptor 
is necessary for activation of certain nucleic 
acid processes, the hormonal response of these 
cells is blocked . 
This drug is given orally in 1 Omg tablets. 
Following oral administration , peak levels occur 
within four to seven hours. The initial half life is 
estimated to be from seven to 1 4 hours. Pro-
Tamoxif en 
Fig. 4. 
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longed blood levels may therefore occur. This is 
thought to be due to concentration and excre-
tion into the bile tract with reabsorption through 
the enterohepatic circulation. 
Toxicity due to antiestrogenic actions in-
clude hot flashes, vaginal bleeding, menstrual 
irregularities, and pruritis vulvae. Non-specific 
gastrointestinal side effects have been de-
scribed such as nausea, vomiting and distaste 
for food . Other toxic manifestations may include 
fluid retention, hypocalcemia, ahd dizziness. 5 
The major indication at present is in pallia-
tive treatment of advanced metastatic breast 
carCinoma. The use of this drug in estrogen-re-
ceptor positive premenopausal women with 
breast cancer is currently being evaluated by 
the National Surgical Adjuvant Breast Project. 
New Combinations 
The addition of these new agents has 
made possible new combinations taking into 
account not only the principle of cell cycle and 
cell kinetics suggested earlier, but also permit-
ting modification of toxicity since many of these 
new agents have toxicity different from many of 
the standard agents in chemotherapy. For ex-
ample, Bleomycin and Tamoxifen have essen-
tially no hematologic toxicity and are attractive 
to use in combination with agents that might 
cause marked hematologic toxicity. Two partic-
ularly interesting new combinations include the 
ABVD regimen (Adriamycin, Bleomycin, Vin-
blastine and 5-(3 , 3-Dimethyl-1-triazene)~imida­
zole-4-carboxamide) used in Hodgkin disease 
and the Cis-platinum-Bleomycin-Vinblastine 
combination used in testicular cancer.6 
The ABVD combination has been shown 
to be approximately equally active to the MOPP 
combination (Mechlorethamine + Oncovin 
+prednisone+procarbazine) used in the treat-
ment of advanced Hodgkin disease. More im-
portantly, there appears to be little cross resis-
tance of the ABVD regimen with the MOPP 
combination making possible a suitable alterna-
tive treatment for MOPP failures. The combined 
use of Bleomycin and Adriamycin has also been 
shown to be active in some recent combinations 
used in non-Hodgkin lymphomas as well. 7 
In testicular cancers the contribution of 
these new agents (Bleomycin and particularly 
Cis-platinum) is even more impressive. While 
several active agents have been available for 
many years including Methotrexate, Acti-
nomycin D, and Mithramycin , the percentage of 
complete remissions was consistently 30% or 
less with no prolonged survivals. The combina-
tion of Cis-platinum-Vinblastine-Bleomycin has 
resulted in complete remission rates of 70% or 
greater with an increased percentage of pro-
longed survivors.8 The evolution of chemother-
apy in the treatment of testicular cancer with 
first the addition of Bleomycin and later the ad-
dition of platinum illustrates the point made ear-
lier that as new agents are introduced in combi-
nation with other effective agents, there is hope 
that still more effective combinations will be 
found in the treatment of other cancers as well. 
Adjuvant Chemotherapy 
Adjuvant chemotherapy is usually defined 
as the use of chemotherapy together with sur-
gery and/ or radiotherapy. As suggested earlier, 
cell kinetics provide a rationale for the use of 
adjuvant chemotherapy. Following removal of a 
tumor mass and a curative resection, the cell 
number should be reduced dramatically. When 
the cell number is relatively low, tumor cells are 
more likely to be actively growing and dividing. 
Since most chemotherapeutic drugs will kill 
cancer cells actively "in phase" in the cell 
cycle, it should follow that the smaller the tumor 
mass, the larger the growth fraction and the 
more likely the cells are to respond to cytotoxic 
drugs. The fact that only one cell is needed to 
theoretically kill the host, and the fact that 
chemotherapeutic drugs kill in a first-order ki-
netic manner, further supports the rationale for 
chemotherapy in the adjuvant setting . A number 
of experimental studies using mouse and rat tu-
mor models have substantiated the value of ad-
juvant chemotherapy in prolonging survival. 9 
Clinical trials have now demonstrated a 
definite role for adjuvant chemotherapy in at 
least delaying the occurrence of metastases in 
premenopausal patients with breast cancer. It is 
still somewhat early to evaluate the overall ef-
fect on survival, although it does not appear to 
be as promising as originally hoped. Two regi-
mens have been used in extensive adjuvant 
studies in breast cancer in this country and 
abroad. The American study has utilized the al-
kylating agent L-phenylalanine mustard, while 
the European study from Italy has utilized the 
combination of Cyclophosphamide, Methotrex-
ate and 5-fluorouracil. Both studies have dem-
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onstrated a definite role in premenopausal can-
cer, although the role in _postmenopausal 
cancer is somewhat less clear. 1 0 
On osteogenic sarcoma there has been a 
dampening of the original enthusiasm for adju-
vant chemotherapy. The initial regimens used 
during the past five years have included the use 
of Adriamycin with and without other agents 
and the use of high-dose Methotrexate. In these 
studies there has been the suggestion that 
again metastases may be delayed; but in this 
case it appears much less likely that any overall 
improvement of survival has resulted. 9 
For other tumor types the role of adjuvant 
chemotherapy . at present remains much less 
clear. There is, however, the hope that with 
newer agents resulting in more effective combi-
nations, there will be increased effectiveness of 
these drugs used early in the course of the dis-
ease with the anticipation that not only the onset 
of metastatic lesions will be delayed but also 
that survival time will be prolonged. 
Receptor Status 
Over the past several years there has 
been widespread acceptance by the medical 
and surgical community of the importance of 
obtaining breast tumor specimens at the time of 
surgery for assessmerit of estrogen as well as 
possibly other hormonal receptors. 11 The estro-
gen receptor assay has been shown to have a 
positive correlation greater than 65% with re-
sponse to hormonal therapy in several large 
studies recently completed . Fwrthermore, pa-
tients with estrogen~receptor negative tumors 
appear not to respond to hormonal therapy. The 
most important impact of this receptor data is 
that approximately a third Of all breast patients 
with metastasis are estimated not to respond to 
hormonal therapy. With the use of the hormonal 
-receptor assays, patients who are estrogen-re-
ceptor negative may be spared ineffective ther-
apy and may be begwn on more effective cyto-
toxic chemotherapy at an earlier point . 
Less clear is the importance of estrogen-
receptor negative status in premenopausal 
patients. Recently it has been suggested in a 
retrospective study conducted at the National 
Cancer Institute that estrogen-receptor negative 
patients may actually respond better to chemo-
therapy than estrogen-receptor positive 
patients. This study, however, has been con-
tradicted by yet another retrospective study. At 
th~ present time prospective studies are needed 
to clarify this hypothesis, and no recommenda-
tions can be made. 12 
Prediction of Drug Response 
For many years there has been the hope 
that one could test tumor cells, much as one 
tests bacteria cultured from an infected patient, 
thereby making a more rational choice of the 
agent or agents to be used. To some extent this 
approach has already been adopted in breast 
cancer where the presence or absence of estro-
-gen receptors in the tumor specimen from a 
particular patient may determine whether hor-
monal therapy will be used. Recently a new 
method was d~monstrated which permits tumor 
cells, obtained from specimens at the time of 
surgery, to be cultured so that drugs may be 
tested for possible effect. While only a limited 
number of cases have been studied at the pres-
ent time , data in multiple myeloma and ovarian 
cancers suggest that the possibility exists that 
indeed a predictive test may be possible, 13 
thereby at the very least preventing the use of 
ineffective cytotoxic drugs and possibly deter-
mining effective drugs that may be used in the 
treatment of the individual patient. Again re-
search will be conducted in the 1980s which 
will further clarify the usefulness of this new 
method. 14 
Long-Term Effects of Chemotherapy 
While the immediate and idiosyncratic ef-
fects of the various chemotherapeutic agents 
have been well known , it is now clear that some 
of these drugs, particularly the alkylating agents 
and those drugs that intercalate into DNA, may 
result in the development of secondary neo-
plasms. These usually occur four to five years 
after the initial chemotherapy has been com-
pleted . 15 The implication is that the very patients 
- who have been ''cured'' by chemotherapy have 
then gone on to develop neoplasms secondary 
to the initial chemotherapy. This has now been 
seen in an increasing number of chemore-
sponsive tumors; eg with the use of alkylating 
agents in multiple myeloma or with alkylating 
agents with or without radiotherapy in Hodgkin 
disease. 
The effects of radiotherapy have long 
been known to be associated with secondary 
neoplasms so that patients receiving radio-
therapy and chemotherapy with agents which 
84 / DIASIO: RECENT ADVANCES IN CANCER CHEMOTHERAPY 
interfere with the DNA structure may be espe-
cially at risk. With the development of more ef-
fective combinations, it is hoped that some of 
the agents responsible for these catastrophic 
toxicities may be removed and replaced by 
' 'non-carcinogenic'' drugs. 
Lastly, there will be a need to review the 
use of certain potentially ''carcinogenic'' agents 
in adjuvant regimens, especially in those pa-
tients who may indeed have been cured by sur-
gery. With more experience it is hoped that the 
more toxic agents may be removed from these 
combinations as well. 
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Cancer is the number two killer in the 
United States and will probably account for 
some 400 ,000 deaths in 1982 . The lung has 
now achieved the dubious distinction of being 
the most common site of cancer in men and 
causes the most deaths. Cancer of the colon 
and rectum is the second most common cancer 
in both males and females combined, whereas 
carcinoma of the breast and uterus pre-
dominate in women. 
The incidence of most cancers has been 
rising rather slowly over the past several dec-
ades for reasons that are not clear, possibly be-
cause of increasing contamination of our envi-
ronment by chemical carcinogens, air pollution, 
and prescription drugs. In males lung cancer 
has dwarfed the incidence of most of the other 
tumors; even in females there is an ominous re-
cent sharp angling of the curve upward . Carci-
noma of the stomach and carcinoma of the cer-
vix have markedly declined during the past 
several years, but the reason for this is unclear. 
Perhaps the decline may be related to some 
dietary factor which has been eliminated due to 
better techniques for preserving or preparing 
meat. 
It is useful to examine the anticipated five-
year cancer survival rates for specific sites 
taken from the Surveillance Epidemiology End 
Results Group of the National Cancer Institute. 
Many localized cancers, particulary those of the 
bladder, breast , colon , larynx, prostate and 
uterus, show prolonged survival times. The no-
table exception is the lung with a five-year sur-
vival of only 23%, even if the tumor is localized 
at the time of surgery. The American Cancer 
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Society purports to indicate that this means tu-
mors should be detected earlier . An alternative 
explanation is that those tumors which remain 
localized are biologically less malignant and 
grow more slowly, and therefore have a greater 
likelihood of being found at a time when they 
have not yet spread. 
· What is not emphasized is that for pros-
tatic neoplasms and lung cancer , probably 80-
85% of the tumors are disseminated when first 
discovered, so that the localized cancers are in 
the distinct minority. Once a tumor has been 
disseminated, the chances for prolonging sur-
vival are greatly diminished. 
During the past five years there have been 
no substantially new modalities of therapy. In 
some areas our surgical techniques are already 
extremely refined while in other areas they con-
tinue to evolve, as in the currently expanding 
use of microsurgery in pituitary, pineal , ocular, 
and laryngeal tumors. There has been a prolifer-
ation of endoscopists, and it is now a rare endo-
bronchial, colonic, or jejunal lesion that man-
ages to escape direct visual inspection through 
the endoscope befpre it is removed . 
Substantial advances have been made in 
diagnostic radiology, particularly in the areas of 
CT scanning and ultrasound . Radiotherapeutic 
techniques have gradually evolved as well. 
Treatment planning is better because of newer 
computer-simulated models. The high-voltage 
linear accelerator and the use of newer heavy 
particles, such as the neutron and photon 
beams, have also given a higher therapeutic in-
dex in specific problems. 
The cumulative impact of these refine-
ments in surgery, radiology, and chemotherapy 
has been substantial. For example, in radio-
therapy there has been great improvement in 
survival for those who have tumors that are both 
radiosensitive and tend to be localized. There is 
little question that we have markedly improved 
the therapeutic index in retinoblastoma, testicu-
lar carcinoma, Hodgkin disease, and have im-
proved the situation in head and neck cancer, 
as well as prostate, bladder, ovary, and tonsil 
cancer. 
More striking is that a number of cancers, 
particulary congenital trophoblastic tumors, Bur-
kitt lymphoma, testicular neoplasms, Wilms 
tumor, and neuroblastoma are now being cured 
routinely by chemotherapy. Hodgkin disease 
has been heavily affected by appropriately used 
radiation therapy and chemotherapy, some-
times in combination. Survival of patients with 
Hodgkin disease in 1979 is probably greater 
than 50% for all tumors. Chemotherapy is also 
generally agreed to be useful for palliation of 
prostatic carcinoma and breast carcinoma as 
well as chronic lymphocytic leukemia, lympho-
sarcoma, and acute myeloblastic leukemia. 
We have not changed survival times of pa-
tients with the more common solid tumors to 
any extent despite the progress we have made 
in controlling the fluid tumors of leukemia and 
lymphoma. Little progress has been made in 
prolonging survival of patients with solid organ 
tumors, particularly those of the lung, colon, 
and genitourinary tract which are the most com-
mon and which far outnumber leukemias and 
lymphomas. Nevertheless, a great deal of prog-
ress has been made during the past decade. 
We have learned much about the biologi-
cal behavior of human tumors, some from ani-
mal experimentation and some from carefully 
designed cooperative clinical trials. There are 
two important concepts which have had consid-
erable impact: first, the concept of micrometas-
tases and their relationship to tumor burden, 
particularly in breast cancer; and second, differ-
ences in biologic aggressiveness among histo-
logically-similar types of cancer as exemplified 
by Hodgkin disease. 
With respect to the concept of total tumor 
burden and micrometastases, it should first be 
stressed that all tumors, when discovered, are 
actually in a fairly late stage of their growth. If 
we assume that a tumor begins as a single cell 
and continues doubling and growing ex-
ponentially, it has already divided approximately 
30 times to reach a size of about 1 0° or 1 09 
cells and a weight of about one gram. A one-cm 
tumor nodule is probably at the limit of detection 
either by palpation or x-ray. 
Treatment may accomplish any of several 
goals. An effective treatment may shrink the tu-
mor drastically, perhaps by a factor of a thou-
sand, but unless every cell is destroyed, it is al-
most certain that the tumor will recur. If the 
recurrent tumor tends to follow the same kinet-
ics as the earlier tumor, its rate of growth will be 
the same. This is usually the case except in the 
case of metastatic tumors; such tumors usually 
grow faster. In general, the more substantial the 
response, the longer the survival. 
In some instances effective treatment, 
such as hormonal therapy, may drive the tumor 
into a state of dormancy or quiescence, so that 
its rate of growth is changed, but at some later 
point when it resumes autonomous growth , it 
will again grow at a rate similar to the rate it ex-
hibited initially or even faster. 
Many chemotherapists have spoken of 
eradication of the last tumor cell. We now know 
that this is somewhat naive and may perhaps 
apply to one or two tumors in which most all the 
cells are actively growing and are susceptible to 
a chemotherapeutic agent. In the most common 
solid tumors such as those of the lung, breast, 
and colon, only a portion of the cells are in 
cycle and are susceptible to chemotherapy at 
any one time. 
It is likely that many tumors continually 
shed cells into the circulation, and the cells that 
are shed must be counted in the total tumor bur-
den. There was an experiment which was per-
formed in mice in which an implanted mammary 
carcinoma was allowed to grow to the size of 
700 mg. At that time surgery was performed, 
and all visible tumor was excised. Nevertheless, 
it was clear that there must have been microme-
tastases at sites distant from the resection be-
cause with large tumors essentially no mice re-
mained tumor free one month after surgery. 
There is a striking parallelism between this 
experiment and a similar study performed in hu-
mans where the tumor burden was simply mea-
sured by the number of positive lymph nodes 
found during surgery in patients with breast car-
cinoma. As the number of positive nodes in-
creased , the ten-year survival of these patients 
fell drastically. A number of surgeons claim that 
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patients with higher numbers of positive lymph 
nodes do poorly because the nodes act as a 
secondary focus of disease and that more ex-
tensive operations should be performed. 
If this thesis were correct, then there 
should be clearly demonstrable differences be-
tween patients that had different types of opera-
tions. The newer operation that is now being 
performed is a simple or total mastectomy in 
which just the breast is removed, but the con-
tents of the axilla are not taken (they may be 
biopsied but are not removed), and the pecto-
ralis muscle is also preserved. This is to be 
compared with a standard radical mastectomy 
in which the entire contents of the axilla are re-
moved together with the pectoralis muscle, 
leaving only the intercostal muscles and the ribs 
after mastectomy. 
After five years the National Surgical Adju-
vant Breast Protocol Groups have shown no dif-
ference in survival among almost 1 ,000 pa-
tients who underwent different types of 
mastectomy. This would affirm that the reason 
for failure of breast carcinoma treatment is due 
to distant metastases which are not visible at 
the time of surgery. This concept has had an 
enormous impact on the area of breast cancer 
because it has led to trials of adjuvant chemo-
therapy which have, in fact, greatly improved 
survival where surgery could not. 
In Hogkin disease we have a similar situa-
tion but with one additional complicating factor. 
First, we do know that in Hodgkin disease the 
total body burden of the disease does bear a 
close relationship to prognosis. Early in the 
treatment of Hodgkin disease, many of the ob-
servers at Stanford and other institutions con-
cluded that most Hodgkin disease spread by 
contiguity and that the disease essentially could 
be cured if radiotherapy could be applied to all 
the involved fields plus an additional margin of 
safety around the field. Thus, Stage I could be 
treated by radiotherapy to the axilla and the me-
diastinum. 
An additional important prognostic factor 
in Hodgkin disease is the histologic type of the 
disease. Four current histologic classifications 
are recognized : lymphocytic predominance, 
nodular sclerosis, mixed cellularity, and lym-
phoid depletion. In this progression the last type 
has the most Reed-Sternberg cells, the least 
lymphocytes, and the worst prognosis, no mat-
ter what the stage. Each of these histologic pre-
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sentations is closely associated with a specific 
stage of the disease; for example, lymphoid de-
pletion is extremely rare in Stage I and is most 
found in Stage Ill or IV. On the other hand, lym-
phocytic predominance is usually found as 
Stage I or Stage II. Although there is some over-
lap between histologic patterns of the disease, 
in the main the histologic patterns tend to per-
sist for long periods of time. 
It is beginning to appear that Hodgkin dis-
ease may consist of at least four separate clini-
cal entities, each of which pursues a different 
course and for which different management 
strategies are indicated. For Hodgkin sarcoma, 
which tends to disseminate rapidly and prob-
ably does not spread by contiguity, localized ra-
diotherapy would be useless and systemic che-
motherapy would be the more effective agent. 
Similarly, for lymphocytic predominance, che-
motherapy would probably represent too much 
treatment. An important corollary has been that 
the presence of systemic symptoms indicates 
that the disease is aggressive and probably will 
also require systemic treatment . Thus, even if 
the disease is Stage II during intensive investi-
gation but systemic symptoms are present, the 
recurrence rate after radiotherapy only is high 
so that chemotherapy should be considered 
even at that early stage. 
There are other examples of tumors of dif-
ferent biologic aggressiveness. It is easy to re-
call the difference in aggressiveness, growth 
rate and prognosis in patients with estrogen-re-
ceptor positive and estrogen-receptor negative 
breast cancer. In malignant melanoma as well, 
it has become apparent that certain types of 
melanoma, particularly the lentigo maligna or 
the superficial spreading melanoma, are much 
less virulent than the nodular melanoma. This 
undoubtedly will be important at a later time in 
treatment, but as yet no effective treatment regi-
men has been designed for any of these stages. 
Another important topic for which great in-
terest has been generated during the past dec-
ade is that of the possibility of immunotherapy, 
that is to say, that of immunizing the patient 
against his own tumor. Unfortunately, this treat-
ment will also have to await the future because 
there is no firm evidence that immunizing pa-
tients with their own tumor in any way has al-
tered survival or produced regression of the dis-
ease on its own. When used in combination with 
chemotherapy, most controlled studies have not 
indicated that there is any additional benefit of 
adding immunotherapy, although the work is 
not yet completed. One of the important divi-
dends of immunotherapeutic research has been 
the notion that there are certain antigens on the 
surfaces of tumor cells which may be important 
in diagnosis and detection. 
The carcinoembryonic antigen (CEA) is a 
specific antigen which is represented on the 
surface of colonic tumors and also on the sur-
face of the fetal colon as well. The tum9r sheds 
CEA into the serum, and this can be detected 
by radioimmunoassay. Whereas CEA levels 
have not been found to be particularly useful in 
the detection and screening of coionic carci-
noma, they have been valuable for following the 
course of the patient after surgery. Typically, 
normal patients do not have CEA levels above 
five nanograms per ml; colon cancer patients 
. may have much higher levels2 If resection is 
successful and complete, the levels fall rapidly 
after operation . In 30~40% of cases, the CEA 
rises several months before recurrence is clini-
cally detectable. 
In acute myeloblastic leukemia we have 
been carrying out similar experiments at this in-
stitution in conjunction With the University of To-
ronto, and we have been performing tests on 
bone marrow of leukemia patients in remission 
to determine whether we mjght predict relapse 
at an earlier time. Some of our data on 43 pa-
tients will soon be published in the New England 
Journal of Medicine. 
This suggests that tests can be devised 
which will pick up impending relapse in patients 
with myeloblastic leukemia approximately four 
to five months before the tumor appears in the 
bone marrow. We hope to exploit this fact by 
applying reinduction chemotherapy at an earlier 
stage. 
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INTRODUCTION 
Colorectal carcinoma accounts for the 
majority of all gastrointestinal cancers and is the 
second leading site of cancer, excluding skin 
cancers, in overall incidence in the United 
States. 1 Cancer of the stomach, although de-
creasing in frequency, is still an important cause 
of morbidity and mortality. Unfortunately, data 
from large numbers of patients such as can be 
found in Cancer Patient Survival Report No. 5 
show only very modest increases in survival for 
patients with th~se diseases in recent years. 2 
Gastric Carcinoma 
Most patients who develop gastric cancer 
have regional or distant disease at diagnosis. 
The presence of regional nodal involvement is 
almost synonymous with incurability since virtu-
ally all these patients are either non-resectable 
at the time;i of operation or rapidly develop sys-
temic recurrences. Any improvement in treat-
ment results would be expected to be produced 
by chemotherapy or immunotherapy rather than 
from localized forms 9f treatment. 
Fortunately, gastric carcinoma is relatively 
responsive to chemotherapeutic treatment, and 
at least four drugs have now been identified as 
active in treatment of this condition, namely 5-
fluorouracil (5-FU), Adriamycin, mitomycin-C, 
and semustine (methyl-CCNU). Although se-
mustine is the nitrosourea that has been most 
extensively used in the chemotherapy of gastro-
intestinal neoplasms, it is still an investigational 
drug and therefore is not always conveniently 
available. Other nitrosoureas that are on the 
market are probably similar in activity. 
Percentage of response and increase in 
survival with single-drug therapy have been 
modest, and for this reason the drugs have 
been combined into a variety of multiple-drug 
regimens. Most of the possible two and three-
drug combinations of the four active drugs have 
been tried. 
Table 1 shows response rates and sur-
vival figures for some of the most extensively 
tested combinations. The combination of 5-FU 
and semustine was one of the first advocated as 
being superior to 5-FU alone in the treatment of 
gastric carcinoma. More recently 5-FU plus 
Adriamycin plus mitomycin-C (FAM) combina-
tions have become more popular. The FAM 
regimen was initially reported to have a 50% re-
sponse rate in gastric carcinoma. The most re-
cent update of over 60 patients indicates that 
the response rate is holding at approximately 
43%. 3 
The FAM regimen (Table 2) is a well-toler-
ated treatment which gives partial or complete 
responses in about one half of the patients and 
benefits other patients by stabilizing the dis-
ease, resulting in prolonged survival for the pop-
ulation of treated patients. Quality of survival for 
many is good, and it is not uncommon to see 
responses lasting for over one year. 
One problem with the treatment is cu-
mulative marrow toxicity which is attributed to 
the mitomycin-C in the regimen . This tends to 
limit the treatment that can be given after the 
first few cycles. The cycles of treatment are sim-
ilar to other day-1 , day-8 treatments given every 
eight weeks. 
Other combinations of these drugs which 
utilize different doses and regimens have also 
been tried. Two of these used at the Sloan Ket-
tering Institute known as MIFA I and MIFA II con~ 
firm that these drugs in combination are effec-
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TABLE 1 
Combinations Used in Treatment of Gastric Carcinoma 
5-FLUOROURACIL + Semustihe 
5-FLUOROURACIL + ADRIAMYCIN + MITOMYCIN-C 
5-FLUOROURACIL + ADRIAMYCIN + Semustine 
5-FLUOROURACIL + MITOMYCIN-C 
ADRIAMYCIN + MITOMYCIN-C 
tive in the treatment of gastric cancer . 4 Table 1 
indicates treatment results of these and other 
combination treatments for gastric cancer. The 
median survival of patients with untreated ad-
vanced gastric carcinoma is four months or 
about 1 7 weeks from diagnosis . Since the fig-
ures in Table 1 show the survival in weeks from 
the time of treatment rather than diagnosis for 
the entire population of treated patients, not just 
the responders, one can see that a doubling of 
the survival time for the better combination is 
achievable. 
Dr Charles Moertel from the Mayo Clinic 
has recently analyzed data combined from sev-
eral cooperative groups. Using a statistical 
model, he concluded that 5-FU and Adriamycin 
contribute most to the treatment of gastric can-
cer. 5 This is a combination that has not received 
extensive use, and the projected value of the 
treatment needs confirmation in a large clinical 
trial. 
Colorectal Carcinoma 
Although there have been a number of at-
tempts to improve results in treatment of colo-
rectal cancer, most of these have been futile or 
have achieved only very modest success. The 
surgical treatment of colorectal cancer has 
been standard for several decades, and al-
though some recent studies indicate that pre-
DAY 1 
F 
A 
M 
TABLE 2 
FAM Regimen 
DAY8 
F 
DAY 29 
F 
A 
DAY 36 
F 
F = 5-Fluorouracil 600 mg/M2 
A= Adriamycin 30 mg/M2 
M = Mitomycin-C 1 O mg/M 2 
Cycles of treatment are repeated every eight weeks. 
Response Rate 
9-45% 
21-43% 
36% 
Med. Survival Weeks 
17-25 
24-34 
22-30 
17 
operative ahd postoperative radiation therapy 
given adjuvantly in high-risk patients would be 
beneficial , particularly in patients with carci-
noma of the rectum , these suggestions have not 
met with widespread acceptance. 
Five-fluorouracil has been a standard 
treatment for colorectal cancer for 20 years , 
and one might summarize the clinical experi-
ence of a number of investigators' attempts to 
improve results by manipulating the 5-FU dose, 
schedule, or route of administration by simply 
stating that no schedule of treatment has been 
definitely shown to be superior to any other.6 
The most common schedules used have been 
daily intravenous. treatments for five days re-
peated at five-week intervals or one intravenous 
treatment administered weekly . 
Administered orally , 5-FU gives response 
rates similar to the intravenous treatments of the 
drug . However, Moertel 7 has reported that the 
duration of response is shorter with the oral 
form of treatment. Absorption is erratic, averag-
ing about 50% . Because of these facts and be-
cause no oral form of treatment has been mar-
keted, use of this drug by this route of 
administration has not gained wide acceptance. 
Response rates with 5-FU in colorectal 
carcinoma average approximately 20%. Two 
forms of therapy which have a response rate 
above 1 0% are the nitrosoureas and mitomy-
cin-C . Other drugs have either had limited use 
in colorectal cancer or have given response 
rates of 1 0% or less, leaving only a few drugs 
that have a significant response rate in this dis-
ease. 
A number of combinations have been de-
vised for the treatment of colorectal carcinoma, 
the more extensively tested combinations 
being : 5-FU with semustine, mitomycin-C or hy-
droxyurea; 5-FU plus semustine plus vincristine; 
and 5-FU plus semustine plus dacarbazine. Re-
sponse rates for the combinations were initially 
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reported to exceed the results of 5-FU alone. 
The combination of 5-FU, semustine and vin-
cristine has been said to have response rates in 
the range of 35 to 40% by at least three differ-
ent groups. 8 •9 · 10 However, as additional studies 
and survival data are reported, the superiority of 
this combination over 5-FU alone has not been 
confirmed. 6 
Median survival for patients after proof of 
incurability is approximately 30 to 32 weeks 
with 5-FU alone, anq for the combinations the 
survival has be.en in the same range . Con-
sequently, the current consensus is that no 
combination of drugs for the treatment of colo-
rectal carcinoma has proved to be superior to 5-
FU alone. At this time other combinations are 
being tried which, it is hoped, will yield results 
surpassing those with only 5·-FU. 
There is controversy regarding whether or 
not 5-FU alone increases survival in patients 
with colorectal carcinoma. To my knowledge, 
no prospective randomized trials have been 
done comparing 5-FU with no treatment in pa-
tients with advanced disease. Used many years 
ago for the treatment of advanced colorectal 
cancer, 5-FU was shown to yield responses and 
was felt to be beneficial , not only in achieving 
these responses but also in extenc;jing the life of 
the patient. No Qne has since been willing to 
compare it to no treatment. 
One can easily demonstrate that 5-FU re-
sponders live longer than non-responders. Ad-
ditionally, retrospective analysis indicates that 
5-FU produces a modest increase in median 
survival in a population of treated patients. 
Moertel' s own data 1 1 demonstrated that 5-FU 
treated patients live longer throughout the entire 
survival curve than matched historical controls. 
This difference was discounted by Moertel who 
stated that there is no evidence showing that 5-
FU prolongs survival , attributing the difference 
to patient selection. This is only an opinion, and 
different interpretations are possible. 
A number of surgical adjuvant trials have 
been conducted in patients with colon and rec-
tal carcinomas. One of the earliest studies uti-
lized thiotepa or fluorodeoxyuridine (FUdR) after 
surgery. This particular study showed no effect. 
However, it is of interest that these patients, fol-
lowed over a decade, had no increase in carci-
nogenicity or other 1<;3.te toxicity which could be 
ascribed to those treatments. 12 More recentiy a 
number of studies have been done utilizing 5-
FU in adjuvant treatment. In the non-random-
ized studies using historical controls, 5-FU was 
reported to produce a beneficial effect 13· 14 ; in 
the randomized studies the 5-FU, in all cases, 
produced a slight prolongation of disea$e-free 
interval and survival in the treated group. 15- 19 
lnitialiy, the difference was judged not to be sta-
tistically significant; however, a recent statistical 
analysis using cumulative results involving 
larger patient numbers resulted in the con-
clusion that there is a statistically significant im-
provement, at least for some subsets of 5-FU-
treated patients in the adjuvant setting. Results 
of these studies are still pending . 
In an article in the Annals of Internal Medi-
cine,20 Ors Weiss and Devita stated that at the 
present time whether or not a patient receives 
adjuvant chemotherapy for colorectal carci-
noma is a decision that needs to be individ-
ualized for each patient. This is primarily be-
cause the results of 5-FU have been marginal at 
best, and the potential benefits of therapy may 
be overridden by a variety of other factors: dis-
ease stage (patients with Duke 's 82 or C stage 
lesions, eg, extension through the muscular 
layer and/ or invoived nodes are customarily 
treated); age of the patient; histologic grade of 
the tumor; economic factors; and convenience 
of travel to the treatment center for the patient. 
Following a trial of adjuvant treatment, the deci-
sion to continue treatment should be based on 
the patient's tolerance tempered by the knowl-
edge of limited survival benefit . 
Other Gas\rointestinal Tumors 
There are three uncommon types of gas-
trointestinal malignancies, all of which show sig-
nificant response rates to treatment with chemo-
therapy. 
Leiomyosarcomas are found in the stom-
ach and in the bowel . Recurrent or metastatic 
tumors respond to treatment with Adriamycin in 
approximately 30% of cases, and if combined 
with dacarbazine, the response rate may be 
1 0% higher. The treatment for metastatic 
leiomyosarcomas of the bowel is the same as 
for other metastatic sarcomas. 
Lymphomas also occur in the gastrointes-
tinal tract, and although their natural history 
may be somewhat different from those origina-
ting els~where, the chemotherapeutic treatment 
is basically similar. Where the histology predicts 
a favorable outcome, treatment would probably 
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consist of cyclophosphamide plus vincristine 
plus prednisone (COP) therapy and the unfavor-
able ones treated in addition with Adriamycin 
and possibly with Bleomycin. 
Carcinoid tumors are also responsive to 
chemotherapeutic treatment. About one third of 
these patients with advanced disease show ob-
jective responses to treatments with 5-FU and 
streptozotocin in combination . More recently 
Adriamycin has been used as a single agent. 
Treatment for this condition is still very much in 
a stage of evolution . 
Other Advances 
The biologic marker known as carcinoem-
bryonic antigen (CEA) which has been devel-
oped for clinical use in the last decade, ~as 
contributed materially to our ability to stage and 
follow patients with colorectal carcinoma. The 
initial hope was that the test would be useful as 
a diagnostic and screening tool. It has not 
proved to be very useful for this purpose. How-
ever, it has been found to be beneficial as a 
prognostic indicator. Patients with high levels of 
CEA prior to surgery will not do as well as pa-
tients with normal levels. It can also be utilized 
to assess adequacy of treatment or to evaluate 
disease recurrence and treatment response. It 
has been suggested that CEA-producing tu-
mors are inherently more likely to metastasize 
and are less controllable by the body's immune 
processes. This biological difference, if con-
firmed , will undoubtedly influence future treat-
ment strategies. 
Table 3 presents data taken from a study 
where 2, 3 7 2 patients of an unselected popu-
lation were screened for malignancy using CEA 
values. 2 1 Seventy-three of these patients were 
TABLE 3 
Use of CEA in Screening an Unselected Population21 
2372 people followed 5 years 
87% False Positive 64% False Negative 
CEA LEVEL 
< 5 ng / ml :?:5 ng / ml 
Developed a 16 11* 25 
CEA related Cancer 
Never developed 2000+ 62 
Cancer 
73 
(3% of total population) 
• two others were found to have incidental cancers not 
related to CEA evaluation. 
found to have elevated CEA levels above 5 ng / 
ml. Workup of these 73 patients resulted in the 
finding of malignancy in only 11 patients. Nine 
had a CEA-related malignancy and two had an 
incidental malignancy. The false-positive rate , 
therefore, was calculated at 87%. 
More disturbing than even the high false-
positive rate was the fact that 1 6 patients who 
were CEA-negative developed a CEA-associ-
ated cancer during the follow-up period for a 
false-negative rate of 64%. Only 3% of the 
2, 3 7 2 patients had elevated CEA levels which 
is consistent with the fact that 95% of a normal 
population are known to have CEA below 2. 5 
ng / ml. (In this population , 97% had the CEA 
level below 5 ng / ml.) The low incidence of can-
cer in this population of 2 , 3 7 2 resulted in the 
high false-negative percentage. CEA testing 
may play a role in screening certain high-risk 
populations, but it is not suitable as a screening 
mechanism for carcinoma of the colon in unse-
lected populations. 
It was originally thought that CEA would 
be specific for colon carcinoma since the anti-
gen was obtained from fetal colonic tissue. 
However, it was soon found that it is non-spe-
cific for colon carcinoma, being elevated in a 
variety of other malignancies including breast, 
lung , pancreas, stomach and bladder carcino-
mas, and in other malignancies. CEA is also 
elevated in patients with liver disease, pancre-
atic cysts, gastrointestinal polyps and other be-
nign conditions. The CEA is not specific for a 
particular primary site and is not even as spe-
cific as one would like for malignancy. 
With the understanding of certain charac-
teristics of biologic markers shown in Table 4, 
CEA tests can be used quite advantageously for 
a number of purposes. In general , biologic 
markers are non-specific for histologic types of 
neoplasms and often are not even specific for 
malignancy. The specificity and sensitivity tend 
to be inversely related. By developing a more 
sensitive assay, more positive results will be ob-
tained in patients with non-malignant conditions 
or with tumor types other than those antici-
pated. In contrast , if normal levels are drawn at 
a higher concentration , the test is more specific . 
For example, most patients with CEA over 1 0 
ng/ml will have a malignancy. 22 The percent-
age of patients with positive markers increases 
with the stage of the disease. Reports of CEA 
elevation in the 90% range are applicable only 
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TABLE 4 
Some Characteristics of Biologic Markers 
1 . In general biologic markers are non-specific for a 
histologic type of neoplasm and often are not even specific 
for malignancy. 
2. Sensitivity and specificity tend to be inversely related. 
3. The percentage of patients with positive markers 
increases with stage of disease. 
4. Not all patients develop positive markers. 
5. Marker status is not a dependent variable in relatipn to 
staging. 
to patients with advanced colorectal carcinoma. 
The figure is much lower for patients with local-
ized or regional disease only. 
Not all patients develop positive markers. 
Only those patients with certain phenotypic can-
cer cell expressions will show marker elevation. 
Other patients having histologically-similar tu-
mors will never be marker positive. Therefore, it 
is futile to attempt to manipulate a test to give 
results 1 00% of the time or to look for new 
markers that will do this. 
The percentage of CEA positivity in pa-
tients with colonic cancer was initially reported 
in excess of 90%. Later the percentage fell, the 
reason being that initially patients with ad-
vanced disease were tested , and in the later se-
ries more patients with earlier stages of disease 
were tested. 2 3 The percentage of CEA elevation 
directly correlates with the stage of disease; 
however, it is not a dependent variable, mean-
ing that the distribution of CEA positives in pa-
tients of various stages has a tendency toward 
randomness. In general, CEA and other bio-
logic markers are not dependent variables in re-
lation to the stage of disease or any other 
known prognostic factor. This means that prog-
nostication is improved by considering marker 
values along with stage, grade of tumor and 
other standard prognostic indicators. 
CEA is also useful in following colorectal 
patients for recurrence. The majority of patients 
who are found to have recurrences will have 
shown at least one CEA elevation greater than 
2 .5 ng/ml more than three months before doc-
umentation of recurrence. One study24 showed 
54% of the patients having this marker positive 
(>2 .5 ng/ml) more than three months prior to 
the documentation of recurrence. If a higher 
positive value (5 ng/ml) is used, 41 % will have 
an elevation three months before clinical tumor 
recurrence. An additional number of patients 
will have markers positive for three months or 
less prior to recurrence. The percentage of pa-
tients who show elevated CEA prior to recur-
rence of colon cancer is higher than in rectal 
cancer. (Table 5). 
In colon cancer only 14% are never ele-
vated prior to documentation of recurrence 
compared to 32% for rectal cancer. While this 
looks quite good as a tool for predicting recur-
rences, it has to be tempered by the fact that 
matched controls also have a high percentage 
of at least one elevated CEA value . The 
matched controls were patients with the same 
age, the same disease, and treatment, who had 
not had a recurrence during periods of equal 
follow-up. Some of these patients will eventually 
turn out to have a recurrence because it is 
known that the CEA can be elevated for as long 
as several years prior to recurrence. Some of 
these patients have random increases in CEA 
value; others have benign causes of the eleva-
tion. 
It is known that patients who receive blood 
products at the time of their surgery sometimes 
develop CEA elevations that plateau and later 
decrease25 secondary to hepatitis or undeter-
mined factors in the absence of acute or 
chronic liver disease. The problem in following 
these patients is to separate those who have 
random elevations or benign conditions from 
those who have a recurrence of malignancy. In 
order to distinguish those with random eleva-
tions, a CEA nomogram has been developed to 
indicate when values are statistically increased. 
Nomograms are published in the literature, 26 ·27 
but to be valid , each laboratory should con-
struct its own based on the precision of its test. 
While the nomogram is useful in differentiating 
patients who have a random increase from 
those with a true increase in CEA levels, repeat-
ing the value several times helps in making this 
differentiation. 
It is important to make a diagnosis of re-
currence earlier using CEA elevations. Some of 
these patients may be candidates for second 
surgery; others will be candidates for radiation 
therapy or chemotherapy. In considering pos-
sible patients for second surgery, it is necessary 
to separate those patients who are going to 
have an operable malignancy from those who 
have random fluctuation of the CEA, benign 
conditions, and inoperable lesions. Using the 
nomogram, one can distinguish most random 
fluctuations . Benign conditions tend to be 
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TABLE 5 
Percentage of Patients With 
Established Tumor Recurrence Who Exhibit 
CEA Elevations 24 
Primary 
Tumor 
Site 
COLON 
RECTUM 
COMBINED 
>2.5 ng/ml 
>3 mos before 
recurrence 
58 
42 
54 
>5 ng/ml 
>3 mos before 
recurrence 
45 
31 
41 
nomogram positive as are both operable and in-
operable malignancies. The operable malig-
nancies and random fluctuations would not be 
expected to have elevated liver enzymes. The 
degree of CEA elevation helps to discern the 
operable and inoperable malignancies. High 
elevations correlate with metastatic disease and 
more specifically with liver metastases. 
To determine operable cases one looks 
for patients with minimal elevations of CEA. In 
one series the mean elevation in the operable 
patients was 6.5 ng/ml compared to 15.5 ng/ 
ml in those who had inoperable malignancy. 28 
Additional information can be gained by looking 
at the character of the rise. If a benign condition 
exists, the CEA tends to plateau at levels usu-
ally less than 1 0 ng/ml. For any type of malig-
nant condition, an exponential rise occurs; the 
slope of the rise for those who are operable is 
less than that for the inoperable ones. The value 
is probably in the range of 0.5 ng/ml/mo or 
less for operable cancers and >1 ng/ml/mo 
for inoperable patients. 29 
>2.5 ng/ml 
<3 mos before 
recurrence 
28 
26 
29 
>5 ng / ml 
<3 mos before 
recurrence 
26 
32 
28 
Never 
elevated 
14 
32 
17 
A factor to be considered in the decision 
for reoperability is the interval between surgery 
and observed CEA elevation. The benign causes 
of the CEA elevations occur earlier after surgery 
than the operable malignancies. 2 1 Any CEA ele-
vations that occur early are more likely to be as-
sociated with inoperability. If they are caused by 
tumor, they probably are rising at a more rapid 
rate than those that occur later. Patients whose 
CEA elevations occur more than five months af-
ter surgery are more likely to be eligible for re-
exploration . These factors are summarized in 
Table 6. 
It is important to stress that the decision 
regarding reoperation is not based on just the 
CEA level. A careful determination must be 
made that the patient does not have clinical 
metastatic disease by obtaining a chest x-ray, 
liver scan, serum chemistries, and other appro-
priate tests such as sonography, abdominal CT 
scan, and liver biopsy if other tests are nega-
tive. Careful monitoring and testing will exclude 
five sixths of the patients for consideration for 
TABLE 6 
Cause of CEA 
Elevation 
Random 
Fluctuation 
Benign 
Condition 
Operable 
Malignancy 
Inoperable 
Malignancy 
Nomogram 
- or± 
+ 
+ 
++ 
Differential Diagnosis of CEA Elevation 
Liver 
Enzymes 
-
Often 
+ 
-
Often 
+ 
Degree of 
Elevation 
Depends on 
Baseline Value 
Usually 
<1 Ong/ml 
Mean 
6.5 ng/ml 
mean 
15.5ng/ml 
Character 
of Rise 
Not 
Verifiable 
Non 
Exponential 
(Plateau) 
Exponential 
Slope 
<1 ng/ml/mo 
Exponential 
Slope 
> 1 ng/ml/mo 
Time of 
Occurrence 
Post-Resection 
Random 
Median Time 
<5mo. 
) 
Median Time 
>5mo. 
WAMPLER: RECENT ADVANCES IN GASTROINTESTINAL CANCER / 95 
"second-look" surgery. Of the remaining one 
sixth, the resectability rate may be as high as 
30%. 30 Increasing the percentage of patients 
operated on will decrease the resectability per-
centage . The cure rate for the patients who are 
resected a second time is not known. 
A practical strategy for following patients 
with colorectal cancer with CEA assays is pre-
sented. Preoperative levels should be obtained 
for establishing a base line and serve as a prog-
nostic indicator. The test should be repeated 
postoperatively. Two weeks after surgery is 
both convenient and appropriate; however, if 
the CEA level has not returned to normal , the 
test should be repeated. 
Apparently not all CEA values return to 
normal promptly. If they remain elevated, it is 
important to establish a base line for nomogram 
analysis . Subsequently, values are obtained 
every two months for the early detection of re-
currence . After one year the test could be run 
less frequently. If a significant elevation is en-
countered outside the normal nomogram range , 
the test is repeated serially, two or three times, 
to verify elevation and determine, if possible, 
the character of the rise. Concurrently, the pa-
tient is evaluated carefully for metastatic dis-
ease. Selected patients may be candidates for 
surgery. 
In patients who have developed meta-
static disease, CEA can be used for evaluation 
of chemotherapeutic or radiotherapeutic re-
sponse. The CEA appears to be more corre-
lated with tumor burden if its value is below 1 00 
ng/ml. While this correlation is sometimes er-
ratic, it is the most valuable tool available in pa-
tients who do not have measurable disease. 
CONCLUSION 
Chemotherapy has produced significant 
improvement in treatment results for gastric car-
cinoma, but to date only minimal improvement 
has been achieved for colorectal carcinoma. 
Earlier application of radiation therapy, specifi-
cally preoperative and postoperative radiation 
therapy, particularly for patients with carcinoma 
of the rectum, is sufficiently attractive for further 
study. 
The primary area of improvement for pa-
tients with colorectal carcinoma has been in our 
ability to assess the status of the disease and in 
our beginning understanding of the biologic dif-
ferences in patients with the disease. Ultraso-
nography and CT scanning are relatively new 
procedures whose effect on the overall problem 
remains to be assessed . Carcinoembryonic an-
tigen testing is clearly an important advance, 
and there is every indication that other useful 
markers will be developed. 
The net effect of all these developments is 
the increased ability to select patients accu-
rately for given treatments and to follow treat-
ment results more precisely. It is known from 
previous experience that in those diseases in 
which the assessment of results is difficult, 
progress has been slow. Therefore , it is antici-
pated that more rapid improvements in treat-
ments in the coming years will ultimately be re-
flected in the overall survival statistics of these 
diseases. 
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Breast Cancer: An Update 
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Breast cancer comprises approximately 
13 .9% of all cases of malignancy in both sexes 
and 19% in women, in whom it is the common-
est form of cancer . 1 The American Cancer So-
ciety estimates that 11 0,000 women developed 
breast cancer in 1981 , and some 3 7, 1 00 
deaths from the disease occurred. ~ The five-
year survival rate has been improving over the 
past 40 years as shown in Table 11 , but pa-
tients remain in risk of recurrence indefinitely, 
and survival for ten years is generally accepted 
as the minimal time period necessary to estab-
lish the validity of new therapies. 
Data from the first study of the National 
Surgical Adjuvant Breast and Bowel Project 
(NSABP) are shown in Table 2 and indicate that 
the majority of women with breast cancer ulti-
mately succump to the di$ease.3 Thus, although 
only 1 0% of cases present with metastatic dis-
ease (an additional 5% predictably have very 
rapid progression : inflammatory carcinoma, ex-
tensive local or regional disease), over half of 
those undergoing mastectomy will develop re-
currence within ten years. 
The identification of women with either ad-
verse or favorable prognostic features modifies 
these figures considerably . Among the impor-
tant favorable variables are : attainment of 
menopausal status for at least five years ; in-
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creasing age; primary tumors two cm in diame-
ter or less; absence of regional node in-
volvement ; estrogen and progesterone receptor 
positivity and, for estrogen receptors at least , 
absolute amount of receptor; delay between ini-
tial presentation and recurrence; skin or nodal 
local recurrence as opposed to visceral metas-
tasis; and perhaps most important, an overall 
less aggressive biological character of the tu-
mor. 
Adverse prognostic features include: a 
clinical picture of inflammatory carcinoma; con-
current pregnancy; liver metastasis; multiple vis-
ceral metastases at presentation ; brain, men-
ingeal, epidural involvement, or spinal cord 
compression secondary to vertebral collapse; 
lymphangitic pulmonary spread; absence of es-
trogen and , possibly, progesterone receptor; 
failure of previous therapy for systemic disease; 
and inability to withstand the toxicities associ-
ated with chemotherapy or hormonal therapy. 
An excellent review of all phases of breast can-
cer has recently been published .5 
I intend to concentrate on four areas in 
greater detail : 1) the usefulness of receptor as-
says in predicting the response to therapy; 2) 
chemotherapy of advanced metastatic disease; 
3) adjuvant chemotherapy following surgery; 4) 
the usefulness of antiestrogens in hormonally-
responsive disease. 
Receptor Assays 
Steroid hormones are known to act by 
crossing the cell membrane where they bind to 
specific cytoplasmic receptors . The receptor-
steroid complex is activated and translocates to 
the nucleus where it interacts with chromatin. 
TABLE 1 
Five-Year Survival Rates In Breast Cancer 
1940-1949 
1953-1959 
1960-1964 
1965-1969 
53% 
60% 
62% 
64% 
(Note: Adapted from Cutler SJ, Myers, MH, Green SB: 
Trends in survival rates of patients with cancer. N Engl J 
Med 293: 122-124, 1975.) (By Permission) 
As a result of this interaction, RNA synthesis is 
increased and new proteins are synthesized.6 It 
now seems that the appearance of progester-
one receptors in breast tumors is the result of 
estrogen stimulation and is a measure of hor-
monal responsiveness (Table 3). 1 
The presence of estrogen receptor (ER) is 
an important determinant of prognosis inde-
pendent of the effects of age, nodal in-
volvement and primary lesion size (Table 4). 
The ER level is less in the tumors of younger 
women and is less in primary as opposed to 
metastatic tumor (Table 5). 1 
Estrogen receptor positivity successfully 
predicts objective responses to hormonal ther-
apy (Table 6) to the extent that only ER+ pa-
tients should be treated initially with ablation or 
hormone administration. 1 ·8 It is of interest that 
the perimenopausal patient, classically not re-
sponsive to hormonal therapy, tends to have 
lower ER positivity than either the premeno-
pausal or postmenopausal (five years or more) 
patient. Clearly the traditional treatment deci-
sion based on premenopausal or post-
menopausal status alone must be modified to 
include ER status. 
TABLE 2 
Results of Surgical Treatment Alone 
Ten-Year 
Treatment Ten-Year 
Failure Rate 
Negative nodes 24% 
Positive nodes: 
1-3 65% 
4 or more 86% 
All 76% 
All patients 50% 
(Note: Adapted from the first NSABP Protocol) 
(By Permission) 
Survival 
65% 
38% 
13% 
25% 
46% 
TABLE 3 
Objective Response to Endocrine Therapy 
No. Responding/ 
Estrogen-Receptor Negative/ 
Progesterone-Receptor 
Negative 
Estrogen-Receptor Positive/ 
Progesterone-Receptor 
Positive 
No. % 
Evaluable Response 
9/ 63 14% 
67 / 91 74% 
(Note: Adapted from McGuire WL: Hormone receptors: 
Their role in predicting prognosis and response to endo-
crine therapy. Semin Oncol 5: 428-433 , 1978) 
(By Permission) 
Chemotherapy of Advanced Breast Cancer 
A large number of chemotherapeutic 
drugs have been shown to produce objective 
responses defined as partial and complete re-
sponses (Table 7). Table 8 lists a number of the 
commonly used agents and responses. The 
early studies of Greenspan and others sug-
gested that combination therapy was consid-
erably more effective, and therefore the initial 
chemotherapeutic treatment is almost always a 
combination, most commonly Cytoxan-Metho-
trexate-5-fluorouracil (CMF). The CMF combina-
tion shown in Table 9 is based on an Eastern 
Cooperative Oncology Group (ECOG) protocol 
with 49 /93 patients responding. Complete re-
sponses lasted a median of eight or more 
months, partial responses four to eight months. 
Many oncologists, including myself, use less 
Methotrexate, 30-40 mgm/M2 , and one series 
TABLE 4 
Estrogen Receptor and the Prognosis for Early 
Recurrence of Breast Cancer 
Category 
Age: 
Less than 50 
Over 50 
Nodes involved: 
0 
1-3 
4 or more 
Size of primary: 
Less than 2 cm 
Greater than 2 cm 
Recurrence at 18 months(%) 
Estrogen- Estrogen-
Receptor Receptor 
Negative Positive 
34 14 
35 8 
12 6 .5 
38 12.5 
62 27.0 
33 0 
31 14 
(Note: Adapted from Table 1, McGuire WL: Semin Oncol 5: 
428, 1978, and Knight WA, et al: Cancer Res 37 : 4669, 
1977 .) (By Permission) 
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TABLE 5 
Distribution of Estrogen Receptor in Primary and Metastatic Breast Cancer 
Primary Biopsy Metastatic Biopsy 
Age: Under50 50 or over Under 50 50 or over 
ER level : 
Under 3 37% 23% 52% 31% 
3-10 20% 15% 14% 16% 
11-1 00 41% 36% 29% 27% 
101-2000 2% 20% 5% 20% 
(Note: Taken from Table 2, McGuire WL: Semin Oncol 5: 429, 1978.) (By Permission) 
showed a 62% respon$e rate with CMF using 
Methotrexate at 40 mgm/M 2 . 
There is no doubt that the single most ef-
fective drug is doxorubicin hydrochloride (Adria-
mycin(R)) with reported response rates of up to 
45%. Combinations using Adriamycin also show 
a higher response rate than CMF or CMFP 
(See Table 9), and some oncologists use CAF 
as the initial treatment. It is, however, desirable to 
have a combination available for use after the 
initial treatment fails, and we have tended to 
reserve Adriamycin for wse in relapse, usually 
combining it with the vinca alkaloid, vincristine. 4 
An exception to this sequence is the pre-
menopausal, ER- patient with extensive vis-
ceral and bone disease. These women usually 
have very rapid, progressive disease, and initial 
treatment with CAF is warranted in an attempt 
to obtain even a small measure of control of 
their disease. 
An additional consideration is the treat-
ment of the ER+ patient with. combined hor-
monal and chemical therapy. Only some 10-
20% of objective responses are complete re-
sponses, but patients achieving complete re-
sponses tend to have longer remissions and 
better survival. Moreover, a small number may 
be curable since the achievement of complete 
response in large numbers of patients has been 
associated historically with the development of 
very long-term survival or cure. Thus attempts 
to increase the number of patients achieving 
complete response and to maintain those in 
complete response for as long as possible are 
now the subject of intense study. 
Legha and his colleagues at the M. D. An-
derson Hospital and Tumor Institute recently re-
ported on 11 6 patients with breast cancer 
achieving complete remission . A marked im-
provement in the number in complete response 
and the duration of complete response was 
seen in premenopausal patients who underwent 
TABLE 6 
Objective Response by Therapy and Estrogen .Receptor 
Therapy 
Ablative Surgery: 
Adrenalectomy 
Oophorectomy 
Hypophysectomy 
Total 
Hormonal Therapy: 
Androgens 
Estrogens 
Glucocorticoid 
Total 
Antiestrogens: 
Nafoxidine 
Tamoxifen 
Total 
ER+ 
#% 
40 / 76 (53%) 
28/43 (65%) 
9/14 (64%) 
77 / 133(58%) 
10/28 (36%) 
38 / 60 (63%) 
15 / 32 (47%) 
63 / 1 20(53%) 
12 / 17 (71%) 
18 / 40 (45%) 
30 / 57 (53%) 
Objective Response/ Evaluable Patients 
ER - Pre-ER patients 
# % (All comers) 
4 / 41 (10%) 
2/74 ( 3%) 
0/12 ( 0%) 
6/ 127( 5%) 
2/22 ( 9%) 
2/ 49 ( 4%) 
0/ 19 ( 0%) 
4 / 90 ( 4%) 
0/ 10 ( 0%) 
0/ 15 ( 0%) 
0/ 31 ( 0%) 
28% 
29% 
33% 
18% 
36% 
29% 
33% 
(Note : Adapted from Table 2, Legha SS et al: Ann Intern Med 88: 69, 1978, and Table 4 , Carbone PP , Davis TE: Semin Oneal 
5: 417, 1978.) (By Permission) 
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TABLE 7 
Tumor Response 
Complete Remission No clinical evidence of active 
Complete Response 
Partial Response 
Stable Disease 
Progressive Disease 
tumor; no subjective evidence 
of disease 
All measurable disease disappears 
50% or greater reduction in mea-
surable tumor in the absence of 
progression or recurrence of 
new lesions elsewhere 
Steady state or response less than 
50% reduction in measurable 
tumor. No increase in size of 
any lesion or appearance of 
new lesions 
Occurrence of any new lesion or 
increase of any measurable 
lesion> 50%, even in the face 
of regressing lesions 
elsewhere 
(Note. Adapted from Carter SK: The design of clinical trials 
in cancer therapy (ed. M Staquet) Brussels: Editions Scien-
tifiques Europeennes, 1972.) (By Permission) 
oophorectomy and received chemotherapy im-
mediately compared to women receiving che-
motherapy when disease progression oc-
curred.9 
An earlier study of adrenalectomy, oopho-
rectomy and chemotherapy by Hoge et al re-
vealed a much higher objective response rate 
(80%) when compared to chemotherapy or hor-
monal ablation alone. 10 These and other studies 
suggest that attempts to increase the number of 
patients in complete response by combined 
therapy may be worthwhile. However, such 
studies remain research protocols, and much 
longer observation will be necessary to assess 
their true value. 
Adjuvant Chemotherapy 
The large number of patients failing to 
achieve cure following radical mastectomy sug-
TABLE 8 
Summary of Single Agents Active Against Advanced Breast Cancer 
No. Evaluable No. Objective Response 
Drug Patients Responses (%) 
Alkylating agents: 
Cyclophosphamide 529 182 34 
Nitrogen mustard 92 32 35 
Phenylalanine mustard 86 20 23 
Chlorambucil 54 11 20 
Thio-TEPA 162 48 30 
Antimetabolites: 
5-Fluorouracil 1263 324 26 
Methotrexate 356 120 34 
6-Mercaptopurine 45 6 13 
Arabinosyl cytosine 64 6 9 
Vinca Alkaloids: 
Vincristine 226 47 21 
Vinblastine 95 19 20 
Antibiotics: 
Actinomycin D 44 5 11 
Adriamycin 193 67 35 
Bleomycin 8 0 0 
Mithramycin 32 5 16 
Mitomycin 60 23 38 
Miscellaneous agents: 
Hydroxyurea 21 4 19 
BCNU 76 16 21 
CCNU 155 18 12 
Methyl CCNU 33 2 6 
Hexamethylmelamine 39 11 28 
lmidazole carboxamide 29 2 7 
Procarbazine 21 5 
(Note: Compiled by Susan J. Mellette, MD, Professor of Medicine, Medical College of Virginia.) 
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Regimen 
CMFVP 
CMF 
CMFP 
AV 
CA 
CAF 
DAV 
TABLE 9 
Useful Drug Combinations In the Treatment of Breast Cancer 
Drug Dosage and Schedule 
Cyclophosphamide 80 mg / m2 p.o. daily 
Methotrexate 20 mg / m2 i.v . weekly 
Fluorouracil 500 mg / m2 i.v. weekly 
Vincristine 1 .0 mg / m2 p.o. daily x 15 (then taper) ! 
Cyclophosphamide 100 mg / m2 p.o. days 1-14 
Methotrexate 60 mg / m2 i. v. days 1 & 8 
5-Fluorouracil 600 mg / m2 i.v. days 1 & 8 
(repeat cycles every 4 weeks) 
Cyclophosphamide 1 00 mg / m2 p.o . days 1-14 
Methotrexate 60 mg / m2 i. v. days 1 & 8 
5-Fluorouracil 600 mg / m2 i.v. days 1 & 8 
Prednisone 40 mg / m2 p.o. days 1-14 
(repeat cycles every 4 weeks) 
Adriamycin 75 mg / m2 i.v. day 1 
Vincristine 1 .4 mg/ m2 i.v. day 1 & 8 
(repeat cycles every 3 weeks) 
Cyclophosphamide 200 mg / m2 p.o. days 3-6 
Adriamycin 40 mg / m2 i.v. day 1 
(repeat cycles every 3-4 weeks) 
Cyclophosphamide 100 mg / m2 p.o . days 1-14 
Adriamycin 30 mg / m2 i.v . days 1 & 8 
Fluorouracil 500 mg / m2 i.v. days 1 & 8 
(repeat cycles every 4 weeks) 
Dibromodulcitol 150 mg / m2 p.o . days 1-10 
Adriamycin 45 mg / m2 i.v . day 1 
Vincristine 1 .2 mg / m2 i.v . day 1 
(repeat cycles every 4 weeks) 
(Note: From Table 3 . Carbone PP, Davis TE : Semin Onco/ 5:417 , 1978.) (By Permission) 
Response Rate(%) 
62 
53 
63 
52 
74 
82 
71 
gests that breast cancer is in fact a systemic 
disease at a very early stage, if not at its onset. 
There is increasing evidence to support a multi-
centric origin for many tumors including breast 
cancer, and it is now apparent that very large 
numbers of cells are shed systemically by even 
small cancers. Moreover, surgical failure results 
in local recurrence in only about 15% of cases, 
and most of these patients eventually show dis-
semination at other sites. 4 Adjuvant chemother-
apy given after surgery is designed to destroy 
disseminated tumor cells and increase the likeli-
hood of cure. 
Two major groups have studies in prog-
ress: the National Surgical Adjuvant Breast Proj-
ect (NSABP) and the National Tumor Institute in 
Milan. 11 · 12 • 13 The initial NSABP trial used a 
single drug , L-phenylalanine mustard, and the 
first Milan study used CMF for 1 2 cycles. Bene-
fit was seen in premenopausal patients with one 
to three nodes involved in both series and for 
four or more nodes in the Milan series. Tables 
1 OA and 1 OB show data updated to four years 
as of May 1 9 7 8 and represent the most recent 
comparative data. No benefit to premenopausal 
women without nodal involvement has been 
demonstrated . The situation for post-
menopausal women is less certain at present 
because the Milan study is reported to show 
benefit for the woman with four or more nodes 
who is able to take 85% or more of the sched-
uled adjuvant chemotherapy. 13 The NSABP 
data do not show benefit . Therefore adjuvant 
therapy should be reserved for premenopausal 
women with one or more positive axillary nodes. 
To date, a clear-cut advantage for three drugs 
and for the duration of treatment has not been 
established, although treatment for six months 
and 1 2 months does not appear much different 
at the present. 1 4 
1 02 / SMITH: BREAST CANCER: AN UPDATE 
Antiestrogens 
A number of steroidal and non-steroidal 
compounds have antiestrogenic effects. Most 
clinical trials have employed the nonsteroidal 
compounds nafoxidine and tamoxifen . The lat-
TABLE 10 
A. Comparison of NSABP /Milan Data 
-Control Patients-
Age/ Positive 
Menopause Nodes 
All Pts. All 
All Pts. 1-3 
All Pts 4 
49 / Pre- All 
50/ Post- All 
49 / Pre- 1-3 
49 / Pre- 4 
50/Post- 1-3 
50/ Post- 4 
% Disease Free 
at Four Years 
NSABP Milan 
51 47 
63 54 
40 32 
43 41 
56 52 
54 49 
35 23 
67 58 
43 42 
5/ 78 
B. Comparison of NSABP /Miian Data 
-Treated Patients-
Age/ Positive 
Menopause Nodes 
All Pts. All 
All Pts. 1-3 
All Pts. 4 
49 / Pre- All 
50 / Post- All 
49 / Pre- 1-3 
49/Pre- 4 
50 / Post- 1-3 
50 / Post- 4 
% Disease Free 
at Four Years 
NSABP Milan 
59 66 
74 74 
40 49 
65 75 
56 56 
86 87 
40 51 
68 61 
40 1 45 
5 / 78 
-
(Note: Courtesy of Dr. Bernard Fisher and the National Surgical Adjuvant Breast Project.) 
ter is commercially available and is believed to 
bind to the estrogen receptor in the cytosol, 
translocate to the nucleus, and bind to chroma-
tin but not release easily. Cytoplasmic receptors 
also are depleted after tamoxifen therapy. It is 
clear that the effectiveness of antiestrogenic 
treatment correlates very well with estrogen-re-
ceptor positivity. An overall response rate of 
about 33% is seen, but the rate in ER+, post-
menopausal patients is as high as 60%. 15 This 
is similar to the percentage of tamoxifen re-
sponse in patients previously responding to hor-
monal therapy. Patients failing to respond to 
hormonal therapy usually do not respond to ta-
moxifen. 
Most studies have been done in post-
menopausal patients, but benefit in pre-
menopausal patients has not been excluded. 
The dose is 1 0 mgm by mouth twice a day and 
is usually tolerated well . Nausea and vomiting 
are seen in some patients (12% in one series), 
hot flushes in about 21 %, hypercalcemia occa-
sionally, and mild platelet count depression 
rarely. 
Synthesis 
The management of the patient with 
breast cancer increasingly depends on careful 
staging taking into account the major prognos-
tic features outlined above. The patient _with lo-
calized disease, small primary and no axillary 
nodes is probably best served at present by 
modified radical mastectomy or radical mastec-
tomy, although studies in progress at a large 
number of centers are beginning to suggest that 
less extensive surgery with radiation therapy to 
the chest wall and nodes may be useful in se-
lected cases. Knowledge of the presence or ab-
sence of axillary node metastasis and the num-
ber of nodes involved is of such central 
importance to prognosis that procedures which 
do not provide this information cannot be con-
sidered useful at this time. 
Premenopausal patients with one or more 
positive nodes but without evidence of meta-
static disease elsewhere should be considered 
candidates for adjuvant therapy. However, the 
question of whether adjuvant cytotoxic chemo-
therapy, immunotherapy, or hormonal therapy 
should be given and for how long remains in the 
investigative stage. Adjuvant chemotherapy 
with CMF cannot be considered of proven value 
for the general population of patients, and every 
effort should be made to include these patients 
in clinical trials to establish the value of adjuvant 
therapy. 
The choice of therapy for the patient with 
extensive disease also has become more com-
plex. ER+ patients of advanced age with cuta-
neous, pleural , nodal, early bone, or nodular 
pulmonary disease may respond well to estro-
gen administration, and on re-exacerbation, 
androgen or prednisone. Approximately 25% of 
these patients will show regression of the tumor 
when estrogen is stopped-the "rebound" 
phenomenon, which has also been described 
after androgen and tamoxifen therapy. 
The premenopausal, ER+ patient cur-
rently is treated with oophorectomy initially and, 
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TABLE 11 
Metastatic Disease 
Premenopausal Postmenopausal 
ER+ ER- ER- ER+ 
Oophorectomy Chemotherapy Estrogen 
Medical adrenalectomy 
Surgical adrenalectomy 
Antiestrogen 
Chemotherapy 
upon relapse, adrenalectomy or hypophysec-
tomy. In a series studied at the Medical College 
\ of Virginia, 16 medical adrenalectomy with amino-
. glutethimide and dexamethasone is almost as 
effective as surgical adrenalectomy and does 
not preclude a response to surgical adrenal-
ectomy when tumor again progresses. A sche-
matic flow sheet to indicate serial treatment 
measures for advanced disease is shown in 
Table 11. 
The presence of extensive long bone me-
tastases or vertebral destruction should be han-
dled with radiotherapy to as small an area as 
possible. Some cases may require prophylatic 
internal fixation of the femur or humerus. 
Prompt laminectomy and decompression of the 
spinal cord in epidural tumors or vertebral col-
lapse is always worthwhile. Chemotherapy 
rather than hormonal therapy will almost always 
be required in such cases because of ttie need 
for rapid control of the disease to ensure contin-
ued ambulation. 
CNS involvement can frequently be han-
dled with moderate doses of radiation to the 
whole brain (3000 rads in 1 0 fractions), but 
meningeal involvement may also require intra-
thecal Methotrexate administration. 
Liver metastases, extensive visceral in-
TABLE 12 
Tenets of Breast Cancer Management 
1 . Make long-term plans for the management of the patient 
at the onset. 
2. Preserve or restore mobility and CNS function. 
3. Treatment of painful lesions is virtually always of benefit. 
4. Start treatment for local recurrences or systemic disease 
early; do not delay. 
5. Neither despair nor hold out unrealistic promise of cure. 
Hope is warranted by the facts . 
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Estrogen rebound 
Androgen 
Androgen rebound 
Antiestrogen 
Progesterone or Corticosteroid 
Chemotherapy 
volvement, bone marrow, or interstitial pulmo-
nary involvement present almost insur-
mountable management problems. However, 
some patients with liver metastases and marked 
liver dysfunction respond to cytotoxic drugs and 
these should be instituted . When the situation is 
desperate, doxorubicin containing regimens 
with their higher initial response rate are the cur-
rent choice. Extensive involvement of more than 
one organ requires cytotoxic drugs for systemic 
effect and radiation of painful or obstructing 
masses of tumor. 
Corticosteroids provide some short-term 
palliation of the patient with interstitial pulmo-
nary involvement. When bone marrow in-
volvement with persistent low blood counts pre-
cludes full doses of multiple drugs administered 
on the usual time schedules, reduction of doses 
and/or the number of drugs may still provide 
some means of control . 
Some general tenets of management of 
the patient with breast cancer are summarized 
in Table 12 . In all cases the most critical aspect 
of management is the close support of the pa-
tient by an understanding and sympathetic phy-
sician. 
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Tapping the Tube 
SARA KAL TREIDER, MD 
The Old Way$ 
Before percussion and mediate ausculta-
tion were discovered, methods of physical ex-
amination-in particular chest examination-
were limited. Only observation was used with 
any regularity. From the time of Hippocrates, 
palpation and direct auscultation had been used 
sporadically to detect heartbeats but had not 
proved to be of practical value because clini-
copathological correlation had not yet been es-
tablished. At last, when a new method called 
percussion was conceived by Auenbrugger in 
1 761, it was ignored for almost forty years. Not 
until the French School evolved did percussion 
become established, largely through Corvisart, 
Napoleon's private physician . Coincident with 
the revival of percussion, Laennec, another 
physician of the French School, invented the 
stethoscope and mediate auscultation . How re-
markable that these two methods of chest ex-
amination came into use at the same time and 
in a period of history when chest disease--es-
pecially tuberculosis-was rampant! 
Until the mid-seventeenth century system-
atic instruction in clinical examination was non-
existent; no patient contact was required for 
medical training or degrees, and it was neces-
sary to pass only an oral test. Two great clini-
cians, Sydenham and Boerhaave, who prac-
ticed in the seventeenth century, helped to 
change this pattern and emphasized the impor-
tance of observation as a method of clinical ex-
amination. 
Thomas Sydenham (1 624-1 689), an 
Englishman , had barely begun his college ca-
reer when it was interrupted by the Civil War. 
[I should like to acknowledge the help, encourage-
ment and inspiration given to me by Dr G. J. Cunningham 
and Dr F. J. Spencer.] 
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Four years later when the war between the King 
and Parliament was over, Sydenham felt too old 
to start a college education again . "At a loss for 
a career," he decided to study medicine at Ox-
ford. 1 Because of his war experiences and his 
brief formal medical education, Sydenham's 
approach to medicine was practical and rela-
tively unspoiled by the old theorizing which was 
popular until his time. Sydenham realized the 
need for practical clinical study as he expressed 
in his words: '' .. . the human mind is far too 
limited in its ability and knowledge to settle the 
great problems of what disease is, and why 
there should be disease. While we debate such 
questions there are sick men who need help. 
.. . The place to study disease is at the bedside 
of the sick man : by observation and experience 
we can learn the nature of disease. " 2 He re-
corded thorough observations on many dis-
eases including scarlet fever, measles, chorea, 
smallpox, malaria, and dysentery, but his mas-
terpiece was a meticulous description of gout, a 
disease from which he himself suffered . Be-
cause his style of clinical observation and de-
scription resembles that of Hippocrates, Syden-
h am has earned the title the ''English 
Hippocrates.' '3 
Hermann Boerhaave (1668-1 738) also 
stressed clinical observation and popularized 
bedside medicine. He was born in Holland, the 
son of a clergyman, began his studies in theol-
ogy at Leyden , and, becoming interested in the 
sciences and medicine , he resolved to become 
a doctor. Respected and loved by his pupils as 
a physician, he was able to promote new ideas 
on the nature of disease. "A disease," he said, 
"is a physical thing and its cause is also a phys-
ical thing . . . which induces a change in the 
solids and fluids of the body. " 4 Boerhaave was 
a pioneer in associating clinical features of dis-
ease with post-mortem appearances, although 
clinicopathological correlation did not reach its 
ful l potential until later through the work of Mor-
gagni. 
During Boerhaave's time, and still later in 
the eighteenth century, examination of a pa-
tient's unclothed body remained a rarity even in 
the case of infants. Boerhaave, however, after a 
history had produced no clues, would resort to 
physical examination. An account is given of an 
infant taken to Boerhaave with a fever of un-
known origin. After an unrevealing history, he 
demanded that the infant be undressed , 
whereby he discovered a needle in its body as 
the source of infection. 5 Besides observation , 
Boerhaave instituted other tools in his practice 
at Leyden; he used the Fahrenheit thermome-
ter, looked at blood and urine under the micro-
scope, and routinely performed autopsies. 6 
These methods and ideas were propagated and 
spread throughout Europe, and his fame ex-
tended even to China. His students came from 
several foreign countries, and his influence on 
other universities was considerable. Two of his 
pupils, Van Swieten and de Haen, were respon-
sible for the development of the old Vienna 
School, and all the founders of the Medical 
School at Edinburgh trained under Boerhaave. 
Bedside observation and post-mortem examina-
tion became important traditions in these 
schools, and it was in Vienna that Auenbrugger 
studied and made his remarkable discovery. 7 
Percussion 
Leopold Auenbrugger (1 722-1809), born 
at Gratz in the Austrian province of Styria, was 
the son of an innkeeper and often helped his fa-
ther in the inn. He completed his medical stud-
ies under Van Swieten at the Vienna School and 
became an attending physician at the Spanish 
Military Hospital of the Holy Trinity (1751 ). This 
large hospital, the finest in Vienna, provided 
abundant opportunities for clinical observations, 
and over a seven-year period, Auenbrugger 
tested his famous discovery. 8 The idea of per-
cussion came about as Auenbrugger was tap-
ping on wine barrels in his father 's inn to locate 
the fluid level without having to open the bar-
rels. In this manner he could determine when 
the supply was dwindling, the hollow sound in-
dicating emptiness. He ingeniously applied the 
new principle of percussion to his patients and 
found that he could detect consolidation , 
pleural effusion, and even cardiac dilatation. 
Not only did he confirm his diagnostic impres-
sions at autopsy, but he also tested his method 
by injecting fluid into the pleural space in cadav-
ers and then percussing them to find the fluid 
level .9 
Auenbrugger published his findings in 
1 7 61 in " lnventum Novem, " a modest 9 5-
page volume which has become a medical clas-
sic. The full translated title of the book is A New 
Discovery that Enables the Physician, From the 
Percussion of the Human Thorax , to Detect the 
Diseases Hidden Within the Chest. 1 0 Auenbrug-
ger ' s observations are found in Camac 's 
Epoch-making Contributions to Medicine11 and 
are now summarized. First, a description of the 
normal chest sound and its characteristics in 
different areas is presented . In the healthy state 
this sound is like a " stifled drum covered with a 
thick woolen cloth . ' ' Variation according to 
body habitus is explained, the sound being 
more prominent in the lean and almost lost in 
the obese. The technique for percussion is sug-
gested: the chest is "struck slowly and gently, 
with the points of the fingers brought close to-
gether and at the same time extended." Meth-
ods are given for percussing the clothed and 
unclothed chest, positioning the patient, and in-
structing him how to breathe. Next, the dull 
sound called the "preternatural " or "morbid" 
sound is described. In this part an analogy is 
drawn between a cask of fluid and a chest with 
effusion . Other observations relate those dis-
eases producing the dull sound ; for example, 
inflammation of the pleura or lungs, serous, 
purulent, and bloody effusions, pericardia! effu-
sion, cardiac enlargement; and those diseases 
not causing a dull sound ; for example, asthma, 
consumption , small lesions. 
Interestingly, Auenbrugger, with much in-
sight and wisdom, had stated in the preface of 
his book, " I realize ... that envy and blame 
. and even hatred and calumny have never failed 
to come to men who have illuminated art or sci-
. ence by discoveries. " 1 2 Indeed , his master~ 
piece did not immediately achieve the attention 
and success it deserved. Van Swieten , to whom 
Auenbrugger almost dedicated his book, failed 
to comprehend the value of percussion. De 
Haen, who lamented the " obscurity and diffi-
culty of diagnosis of thoracic disease,' ' likewise 
never acknowledged percussion and its possi-
bilities. 13 Others either ignored or grossly misin-
terpreted the "lnventum Novem " as did 
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Rudolph Vogel, an authority in medicine in Got-
tingen, who mistakenly wrote that Auenbrug- · 
ger's percussioh was only a variat.ion of Hippoc-
rates' succussion , and was annoyed that 
Auenbrugger did not give credit to Hippocra-
tes. 14 The succussion splash known to Hippoc-
rates was a sign pathognomonic of sero-
pheumothorax and heard less often with 
pyopneumothorax; it really depended on the 
presence of both air and fluid in the pleural cav-
ity. Hippocrates elicited this sign by shaking the 
patient 's shoulders and either listening from 
arm's length or with the ear to the chest when 
he would hear a "splash" or metallic tone . 
Despite the lack of enthusiasm for his dis-
covery, Auenbrugger lived a happy life. He was 
well accepted among his peers for his con-
geniality and loved by his students for his gener-
osity and compassion. He enjoyed a golden an-
niversary with his wife, a peaceful retirement in 
the suburbs, and died at the age of eighty-
seven . His method was only temporarily put to 
rest and was later revived by the French physi-
cian, Corvisart. Still later, after percussion had 
gained popularity, another French physician 
named Piorry promoted a modified form of 
Auenbrugger's method, mediate percussion , 
which is still used by modern physicians. 
The French School and the New Medicine 
In the last few years of the eighteenth cen-
tury, France was experiencing a Revolution in 
medicine as well as in politics. The philosophi-
cal mood which favored observation, experi-
ence, and skeptical empiricism instead of the 
classical beliefs, carried over into the field of 
medicine and the famous French School in 
Paris. 
All remnants of the old regime were swept 
aside by the Revolution, and the universities 
and medical colleges closed. A few years later 
when France was at war, the shortage of doc-
tors became serious, and the only places avail-
able for training were the hospitals. The hospi-
tals became "the workshops of new medicine," 
and according to the historian Ackerknecht, 
'' .. . it was only in the hospital that the three pil-
lars of the new medicine-physical examina-
tion , autopsy, and statistics could be devel-
oped . " 15 
The hospital clinical training as formulated 
during this period sounds surprisingly similar to 
today's attending round . "The professor would 
108 / KALTREIDER: TAPPING THE TUBE 
pause at the bedside of each patient long 
enough to question him and examine him prop-
erly; he would draw the students' attention to 
the diagnostic signs and the important symp-
toms of the disease . . . . '' 16 The students 
would "read little, see much, and do much," 
learning as they practiced at the bedside. 17 
Thus the French School gave birth to medicine 
as it is practiced today, produced many great 
physicians, and became the leadihg school in 
Europe. 
The Revival of Percussion 
Jean Nicolas Corvisart (1755-1821) was 
an eminent figure in the French School, and as 
a proponent of percussion and teacher of Laeh-
nec, he became ''the connecting link between 
the men who did the most for the practical sci-
ence of medicine' '-Auehbrugger and Laen-
nec .18 Corvisart began His career in surgery and 
anatomy but then turned to internal medicine. In 
1782 he was rejected for a position at the 
Necker Hospital despite excellent qualifications 
because he ref used to wear a powdered wig! 
However, he successfully held positions in sub-
sequent years at the Charite, Ecole de Sante, 
and College de France. 
It was in 1 799 that Corvisart came upon 
Auenbrugger 's work through a book by Eyerel , 
a student of the Vienna School who praised the 
method of percussion . Giving full credit to 
Auenbrugger, Corvisart found and translated 
the original "lnventum Novum" from Latin into 
French, added to it his own commentaries, and 
published the entire work in 1808. Two years 
previously, Corvisart had published a book oh 
heart disease, Maladies du Coeur, in which he 
brilliantly discussed pericarditis, cardiac dilata.:. 
ti on and hypertrophy, cardiomyopathy, and val-
vular and aortic disease. However, by far his 
greatest gift to modern medicine was the revival 
and propagation of percussion, so that by 1825 
it was in use practically everywhere. 19 
In 1804, Corvisart was selected to be Na-
poleon's physician, in part because of the Em-
peror's appreciation of percussion. Corvisart 
was called into consultation for a persistent cold 
bothering Napoleon, who was impressed when 
this great physician used percussion in his ex-
amination. 20 In 1815, following the downfall of 
Napoleon, Corvisart retired from medicine alto-
gether and in 1821 died of a stroke. One of his 
most outstanding qualities was his ability to in-
spire and encourage his pupils and their ideas. 
He closely assisted his students, particularly in 
bedside observation. In this way, Laennec 
came to know and esteem Corvisart and to be-
come his favorite pupil. 
Mediate Auscultation 
Rene Theophile Hyacinthe Laennec 
(1781-1826) was born at Ouimper in Bre-
tagne, a province in northern France. His 
mother, having exposed Laennec to tubercu-
losis, died of the disease when he was six years 
of age. Consumption shortened Laennec 's life 
as well but did not hamper his productivity. His 
father, who was an eloquent lawyer but irre-
sponsible and always in debt, sent his sons to 
live with their rector grand-uncle at Elliant. At 
age 11 Laennec went to Nantes to live with his 
uncle Guillaum Laennec, a physician and fac-
ulty member at the University of Nantes who 
was instrumental in Laennec's decision to study 
medicine. 
Laennec's early education was inter-
rupted by the French Revolution , but at age 19, 
after much deliberation, he went to the re-
nowned Paris School to study medicine. In the 
year that followed, he won two prizes given in 
medicine and surgery at the University of Paris. 
At age 23 he successfully completed a medical 
thesis on Hippocrates. Following his formal 
medical training, he spent four years as physi-
cian at Beaujon Hospital in Paris and then ob-
tained a position at the Necker Hospital where 
he made his famous discovery of mediate aus-
cultation . 
The examination of the chest just before 
Laennec's discovery consisted of inspection, 
palpation, the newly added method of per-
cussion, and immediate or direct auscultation. 
Auscultation in this form was known to Hippoc-
rates but was neither popular nor frequently 
used. It had a number of disadvantages. Some 
patients, if not most, were unwashed or vermin-
infested, making direct contact undesirable. 
Other patients had a voluminous amount of fat 
which rendered the method somewhat less use-
ful; furthermore, direct auscultation proved to 
be an embarrassment to the female patient. 
As immediate auscultation ''shocked his 
decency and modesty," Laennec himself used 
it only in cases of suspected heart disease when 
the heart beats could not be felt by palpation. 2 1 
In his own words, ''(It was) as uncomfortable for 
the doctor as it was for the patient, disgust in it-
self making it impracticable in hospitals. It was 
hardly suitable where most women were con-
cerned and, with some the very size of their 
breasts was a physical obstacle to the employ-
ment of this method .... " 22 
The Tube 
In 1816, Laennec was consulted at the 
Necker Hospital by a young female patient 
thought to have heart disease. On his way to 
visit this patient, he saw several children playing 
on some lumber in the gardens of the Louvre, 
and he was reminded of an acoustic principle. 
As one child tapped on the beam at one end, 
the signal reached the other child with his ear 
on the opposite end. Excitedly, Laennec hurried 
to the bedside of his patient with a cylinder of 
tightly rolled paper tied with string and found 
that by placing this instrument between his ear 
and the patient, he could hear heart sounds 
more clearly than ever before. It immediately 
occurred to him how useful this method might 
be in studying all movements produced in the 
thorax-breath sounds, voice , wheezing, 
pleural and pericardia! effusions. 23 
Laennec called the new method ''mediate 
auscultation," " auscultation" for the method in 
its direct form begun by Hippocrates, and "me-
diate' ' for the interposed instrument. The term 
" auscultate" originated from the Latin "ausis," 
to hear, and " culto," to cultivate, and meant to 
give attention through hearing. 24 Laennec 
named his tool the "stethoscope" combining 
"stethos" meaning chest and " scope" from 
the Greek word meaning to examine. Other 
names initially applied to the invention included 
"a pectoriloquy," " medical trumpet," "the cyl-
inder," or " the tube. " 25 
Laennec and everyone else at the Necker 
Hospital began experimenting enthusiastically 
with the tube. He varied the length, width, and 
central hollow, and decided upon a one-foot 
cylinder with a quarter inch central space which 
he accidentally found to be necessary for listen-
ing to the voice. A solid cylinder, he discovered, 
would suffice for heart sounds, breath sounds, 
and rhonchi ; however, breath sounds and 
rhonchi were augmented with the central hollow 
plus a cupped shape carved at the end. Many 
materials were tried-"ebony, cedar, malacca 
cane, lime wood, glass, various metals, . . . 
gold-beater's skin .. . . '' 26 He even used his 
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cousin's oboe but finally decided a light beech-
wood was his preference.27 
Early in 1 81 8 Laennec, having collected 
his preliminary observations, demonstrated his 
new method and instrument to the Societe 
d'Ecole. Though he thought it was premature to 
publish his findings, he felt he should speak for 
his work as others were mentioning his inven-
tion in various publications. At this time he had 
recorded an outline for his book and was expe-
rienced in separating normal from abnormal 
chest sounds. In the same year he presented 
his findings to the Academie Medecine, which 
appointed a commission for study of the 
method. Laennec continued to accumulate data 
and propose new applications for the stetho-
scope. A key case was that of Madame de 
CMteaubriand who had recurrent hemoptysis 
and had been diagnosed by a previous consult-
ing physician as a consumptive in the terminal 
stage. Laennec , finding no signs of cavitation 
by stethoscope, confidently diagnosed bron-
chiectasis ; CMteaubriand lived to age 75 .28 
This differential diagnosis was encountered now 
and then and was important to the patient as it 
made the difference between a life or death 
prognosis. 
In attempting to expand his method 's ap-
pl ication, Laennec reportedly suggested a 
means of helping deaf-mutes.29 He also, on oc-
casion , extended his professional career to in-
clude auscultating animals. During his country-
side vacations which he took only to convalesce 
from exacerbations of tuberculosis , he was 
seen auscultating his dogs, " Kiss" and " Mous-
tache.'' 
In April 1819, he delivered to the pub-
lisher the final product of his labors, De 
/'auscultation mediate, OU Traite de Diagnostic 
des maladies des poumon et du coeur fonde 
principalement sur ce nouveau moyen 
d 'exploration; also known by the shorter title, 
Traite de /'Auscultation Mediate.30 To provide 
the editor with an ample supply of stethoscopes 
to sell with his book, Laennec spent countless 
hours at his lathe meticulously making the 
wooden instruments. The book was ready for 
sale in August 1 81 9 for 13 francs ; and the 
stethoscopes sold for three francs each .3 1 A fur-
ther edition of his book followed in 1826. 
Laennec's stethoscope flourished in many 
countries: England, where consumption was 
raging , Germany, Italy, Spain, Holland, Swe-
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den, Russia , Poland and even across the Atlan-
tic in America. About 35 years after its discov-
ery, a binaural model was designed by George 
Philip Camman of New York . Other varieties re-
fining the original were developed from time to 
time including the modern diaphragm type. 
Laennec's New Signs 
Laennec described most of the stetho-
scopic signs used in modern medicine; not only 
did he describe them, but as an experienced 
pathologist he was able to correlate them with 
autopsy findings, distinguishing numerous con-
ditions including tuberculosis or pulmonary 
phthisis as it was called then , bronchitis , bron-
chiectasis , emphysema, asthma, pneumonia, 
and pleurisy. Here are some of the signs Laen-
nec left to medicine : 
Aegophony. Greek aix or aegis = goat + 
phone = sound , sound similar to the bleat-
ing of a goat; heard at the upper border of an 
effusion . 
Amphoric resonance. Latin amphora = a jar, 
also has Greek derivation, sound resembling 
that heard when blowing into an open bottle; 
indicates cavity. 
Bronchial respiration . Greek bronchos = wind-
pipe, Latin similar, sound heard over larynx, 
trachea, large bronchi; increased in pneu-
monia and dilatation of bronchi. 
Cavernous respiration . Latin caverna = a cav-
ern , similar to amphoric breathing , hollow 
sound ; indicates cavity. 
Crepitant rcj/es. Latin crepitus = little noises, 
crackling ; pulmonary edema. 
Metallic tinkling. Sound as made by sand falling 
into metal cup; indicates cavity. 
Pectoriloquy. Latin pectus = breast + loqui = 
to speak, voice sounding very close to ear 
through stethoscope; sign of cavity. 
Pleural friction . sound resembling rough sur-
faces rubbing together; heard in tuberculous 
pleuritis . 
Puerile breathing. Latin puer = boy, respiration 
heard in child , sonorous with marked in-
spiration . 
R~les. French r~ler = to rattle , crackling 
sounds; Laennec described them as moist or 
crepitant, mucous or gurgling , dry or so-
norous (snoring) , dry sibilant (whistling) ; 
heard in multiple situations depending on 
character. 
Rhonchus. Greek word-snoring, Latin 
rhonchus = snoring , sound heard in many 
conditions-pneumonia, tuberculosis, bron-
chitis .... 
Vesicular respiration. Latin vesicula = little 
bladder, breath sounds heard over normal 
lung fields except over trachea and main-
stem bronchi. 3 2 
The Test of Time 
Most of the signs Laennec discovered 
with his stethoscope have remained important 
to the modern physician. Some are more fre-
quently used than others; for instance, vesicular 
and bronchial breath sounds, r~les, rhonchi, 
pleural friction rub, and aegophony. Those 
signs associated with cavitary disease, how-
ever, are less often encountered because of the 
decline in advanced pulmonary tuberculosis, 
specifically amphoric or cavernous breathing 
and pectoriloquy. Two terms have wider clinical 
application than realized by _ Laennec: aego-
phony, heard above pleural effusions, is some-
times found in consolidation; pectoriloquy can 
be used to detect early pneumonia, atelectasis, 
and infarction. 
Yet another method of chest diagnosis 
has come to be used since Laennec-the X-
ray. With the X-ray the physician has been able 
to look into the chest and actually see patho-
logic changes. It enables him to confirm with his 
eyes what he has heard with his ears and also 
to detect lesions not producing stethoscopic 
findings. Even so, the stethoscope remains the 
most convenient and the quickest method of 
forming diagnostic impressions, determining the 
need for further diagnostic work-up, and clini-
cally following disease processes in the chest. 
Laennec's auscultation has survived the 
test of time, and along with Auenbrugger's per-
cussion has become a permanent part of sys-
tematic chest examination. The chest and its 
diseases which for so long were mysteries to 
the clinician began to be solved with these 
methods. After Laennec, vast numbers of 
books on chest disease appeared. Though 
Laennec did more to elucidate pulmonary than 
cardiac disease, his invention cleared the way 
for Corrigan and Stokes of the Irish School to 
make further advances in the realm of cardiac 
and pulmonary diseases. Thus, the coincident 
establishment of percussion and auscultation by 
the French School has certainly been among 
the greatest milestones in physical diagnosis, 
adding two new methods to chest examination 
and offering new frontiers for the clinicians who 
followed. 
As a final note, new uses may be found 
for auscultation. A recent author described a 
new variation combined with carotid pho-
noangiography. It consists of auscultating bruits 
with a special microphone connected to an os-
cilloscope. 33 These bruits are recorded graph-
ically and evaluated in terms of percentage ste-
nosis. This is one non-invasive means of 
determining which patients with transient is-
chemic attacks would benefit from caroted arte-
riography. Thus, auscultation, used in its tradi-
tional form with the binaural stethoscope, has 
developed new applications which may expand 
further in the future. 
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Colonial Cultivation and Concoctions 
SARA JONES GOMBERG, MD 
Have you ever wondered how to increase 
the value of your property? One way would be 
to include a well-cultivated herb garden ; that is 
if you were a seventeenth-century colonist. Not 
only were the herbs much sought after for their 
culinary uses but also for their medicinal proper-
ties. Today's medical library may not include a 
collection of botany books, yet botanical knowl-
edge was a large part of early medical tr(lining 
and the mainstay of the " cavalier concoctions " 
used by colonists for medical treatment . 
In gathering together its first 225 settlers 
to go to America, the directors of the Virginia 
Company of England instilled a sense of re-
sponsibility in these adventurers to discover 
plants for medicinals. A few colonists were lured 
by the prospects of a profitable drug trade. After 
all, the Spaniar_ds were doing well and had a 
monopoly on the drugs and spices from South 
America, in addition to the gold. They were 
even attempting to block the transplanting of 
the New World plants. Besides profits, the Vir-
ginia Company did have some concern for the 
health and welfare of these first settlers, and of 
the first 225, seven were medical professionals. 
The medical profession in England had, at 
that time, emerged as three distinct groups: the 
apothecaries, physicians, and barber surgeons. 
The development of these three groups is a 
topic unto itself . Briefly, the word " apothecary" 
goes back to Norman times, meaning anyone 
who kept a shop of such non-perishable com-
modities as spices, drugs, comfits, and pre-
serves. At the time of the " Jamestowne expedi-
tion, '' the apothecaries were incorporated with 
the Grocers Guild , hence the apothecary's in-
~ 
terest in spices and such. In 1 61 7 , James I 
granted the apothecaries a separate charter. At 
various times throughout the seventeenth cen-
tury, the apothecary emerged as not only the 
dispenser of medicine but also as the general 
practitioner of medicine. 
The physicians were the elite of the origi-
nal groups. They did not want to concern them-
selves with " general practice," yet they did not 
want the apothecaries to sell medicine without a 
prescription from a physician . The physician ; in 
a classical sense, was the best educated and 
had behind him the tradition of the Royal Col-
lege, which had been founded in 1518. 
The barber surgeons had been organized 
since 1540 and were the least educated of the 
three. They assumed responsibility for any " me-
chanical " treatment needed by their clients. 
From the three groups; at times rival ing one an-
other, the Virginia Company attracted seveh 
members. These were apothecaries Thomas 
Field and John Harford, the physician Walter 
Russel , and four barber surge0ns: Will Wilkin-
son, Thomas Wotton, Post Ginnat, and Tho 
Cowper. Only one of the barber surgeons was 
included among the 1 44 passengers who first 
came to Virginia in 1607, and the remainder of 
the professionals were members of the second 
sailing in January 1 608 . 
Times were rigorous for these early colo-
nists, and their famines, unfamiliar fevers, and 
flixes took their toll. By January 1 608 , when the 
first supply ship arrived, only 38 of the original 
settlers were still alive. The surgeon who ac-
companied the first expedition is not mentioned 
after 1607 in any extant records . The two 
apothecaries and one physician mentioned be-
fore were not noted in the records, and it is pre-
sumed that they, like the majority of the new in-
habitants , did not survive. Because these 
settlers had to treat their ills as best they could 
with little medical guidance and few materials, 
there was the impetus for them to discover na-
tive plant remedies. 
The colonists made requests to the Vir-
ginia Company to send them medical supplies 
and personnel , but communications being what 
they were, they did not receive their next physi-
cian, Dr Lawrence Bahun , until 1610. Trained 
in Leyden, Bahun was a well-educated man 
who stayed for only one year in Virginia before 
returning to England . It is uncertain how much 
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he added to the well-being of the colony as he 
spent most of his time investigating the medici-
nal properties of the local plants . He experi-
mented with a white clay that he claimed had 
absorbent and "aiexipharmic " properties. His 
vegetable remedies included the abundant sas-
sasfras and Galbanum mechoacon or rubarbum 
alum . Rubarbum alum was thought to be good 
for the " purginge of fleame and superfluous 
matter.'' 
Bohun returned to England with Lord 
Delaware , leaving the colonists without any 
medical authority for the period from 1 611 to 
1 621 . Again , they complained of their plight to 
the Virginia Company. Dr Bohun was appointed 
Physician-General in 1 620 but was killed en 
route when Spaniards attacked the ship on 
which he was traveling. In 1621, John Potts 
was selected to replace him . He was accom-
panied by anapothecary, Joseph Fitch , and on 
his arrival took on one of the colonists , Mr 
Townsend , as an apprentice . But once more di-
saster intervened as Joseph Fitch was killed in 
the Indian Massacre of 1622. There is no rec-
ord of Mr Townsend 's practicing as an apothe-
cary , and indeed , of no practicing apothecary . 
until the eighteenth century. This is probably re-
lated to the collapse of the Virginia Company in 
1624 , after which there would have been a lack 
of organized travel facilities for prospective emi-
grants and no promises of profit which might 
have attracted medical professionals. 
The colonists were, therefore, left to take 
medical care into their own hands both for 
themselves and their families . Anyone who 
showed skill in the treatment of disease or abil-
ity in the use of local plant remedies quickly be-
came recognized. The local Virginia legislature 
responded by passing a law in 1632 that re-
quired the parish minister to assist the sick . Oc-
casionally a supply ship 's surgeon , while in 
port , would care for the sick colonists or might 
even settle in the colony himself. If he did , he 
was generally considered a ship 's surgeon 
" that knows nothing above the common reme-
dies-not acquainted with plants or the other 
parts of the Natural History to be any service to 
the worlde.' ' 
As the p!antation system developed, it be-
came necessary for the owners to become well 
versed ih the local remedies to preserve the 
health of their family and servants. A number of 
publications appeared for the purpose of assist-
ing these owners including Every Man His 
Own Doctor or the Poor Planter's Physician 
printed in Williamsburg in 1734. The Virginia 
colonists were developing their own style of so-
ciety in which the medical practitioner was both 
a tradesman and a craftsman . This combination 
prevented the establishment of the guild system 
under which their English counterparts would be 
either an apothecary, physician , or barber sur-
geon , but not all three. The physicians regarded 
themselves as professionals, the apothecaries 
were craftsmen , and the barber surgeons were 
considered tradesmen . On the other hand , the 
Virginia practitioner did what was needed , diag-
nosed his cases, dispensed his own medicines, 
and engaged in what surgery he could . He was 
a multi-specialist. 
As the colonists started to prosper, less 
time had to be spent on mere survival, and with 
· increasing prosperity a plantation owner might 
be able to afford to send his son abroad for five 
to six years of medical education . Whether 
learning medicine by the apprentice system in 
Virginia or studying at one of the major Euro-
pean universities, the student was still exposed 
to botany which remained a significant part of 
the curriculum . Even those who trained to be 
physicians in the European sense often had 
such titles as surgeon-apothecary or physician-
apothecary when they returned to Virginia to 
practice. Usually these new physicians retained 
their keen interest in botany, not only out of a 
need to find remedies to cure New World ills, 
but also for the purpose of classifying the abun-
dant flora . The improving conditions in America 
gave these developing "aficionados" the op-
portunity to increase their knowledge of plants. 
At that time there was growing world interest in 
the classifica,tion of fauna and flora , and it was 
frequently the physician , astute in botany, who 
made significant contributions. 
Dr John Clayton of Gloucester County, a 
self-educated physician , wrote what is consid-
ered to be the best treatise on American plants, 
namely Flora Virginica. It was first published in 
1 739 in Leyden under the name of a Dutch bot-
anist . Hence, Dr Smith-Barton is credited with 
the first " notable" American treatise on the 
subject - " Elements of Botany, " published in 
1 803. He was a professor of medicine at the 
University of Pennsylvania and was noted for his 
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objections to the popular theory of ' 'similia sim-
ilibus" or " like by like." This implied that every 
country possessed the remedy for the diseases 
which prevailed there. A fine example of this is 
Polygala Senega or rattlesnake root . Not only 
was this plant found in the terrain inhabited by 
the rattlesnake, but the observer, with a little 
imagination , might conclude that the root 
looked like the tail of a snake. 
Both Dr John Mitchell of Urbanna, Vir-
ginia, and Dr Alexander Garden of South Caro-
lina contributed vastly to the describing of new 
genera of plants. Dr Mitchell is credited with 25 
genera of plants, eJ.nd he also described the life 
cycle and reproductive mechanism of that curi-
ous American animal, the opossum. He was 
well educated, having been trained in Edin-
burgh, and subsequently having made contribu-
tions in other areas of natural history. Dr Garden 
also studied at the University of Edinburgh . He 
is described as the "parable of the opportuni-
ties, temptations and limitations of American 
life.'' He was perhaps the most accomplished 
American botanist of his time, yet he never pro-
duced a significant systematic work . Most of his 
correspondence was via letters to other notable 
naturalists, and hence his name appears more 
often than any other Ar:nerican in the famous 
work by the Swedish botanist , Carl Linnaeus, 
entitled Systema Naturae (12th edition). Dr Gar-
den is remembered by many for the sweet smell 
of the gardenia, a flower which bears his name. 
Plant identification and description were 
also tempered by the accepted medical prac-
tice of the time . In 1 760 , Dr William Douglas 
described the traditional approach as " bleed-
ing , vomiting , blistering , purging, and ano-
dynes, etc ., and if the illness continued there 
was repetendi , and finally murderandi. " An-
other physician, John C. Lettsom , who lived in 
England at this time, summed up the common 
theories thus : 
When any sick to me apply, 
I physicks, bleeds, and sweats 'em. 
If after that they choose to die, 
What's that to me? I Lettsom . 
Bleeding was done by the ubiquitous 
leech or by a special instrument known as a 
fleam. The colonists , already concerned with 
preventive medicine, would bleed themselves 
often according to a schedule in hopes of pre-
venting an affliction . There seemed no limit to 
the amount a person could be bled except ex-
sanguination . It has been said that George 
Washington, who had pneumonia, was prob-
ably bled to death as a "cure" for his infection . 
Bleeding may have been popular, but 
equally in demand were emetics. There were 
many ''excellent'' agents available to induce 
vomiting . The most widely used at that time, 
and a drug still recognized today, was tartar 
emetic (antimony potassium tartrate). In addition 
to its properties as an emetic , it was used to 
treat parasitic infections and today is of use in-
travenously as a treatment for schistosomiasis, 
mainly of the japonicum type . Although in-
expensive and effective, its application is limited 
by highly toxic side effects including exfoliative 
dermatitis, toxic liver necrosis, and toxic myo-
carditis . 
lpecacuanha, another popular emetic , is 
well known to today's pediatrician. Its original 
use was not only as an emetic but also as a 
treatment for diarrhea. The native Brazilians had 
recognized its effectiveness in dealing with this 
symptom prpbably in cases of amebiasis and 
sold it in 1658 to the French as a secret remedy 
for dysentery. The source of the "secret" rem-
edy is the dried rhizomes of Cephaetis ipeca-
cuanha or Acuminata ipecacuanhae. 
These two methods, bleeding and vomit-
ing , were used in hopes of ridding the body of 
its poisonous affliction , and if they failed , the co-
lonial physician could resort to blistering . For 
this purpose , mustard seeds were ground and 
mixed to form a paste which was applied to the 
skin in the form of a poultice or plaster. If the 
mustard seed failed to draw the poison to the 
surface, a paste made from dried Spanish Fly 
(Lytta cantharida vesicatoria) was applied to the 
skin . This was considered a powerful vesicant 
and surely would not fail, and if taken internally, 
it had the additional properties of a diuretic and 
aphrodisiac . 
Diaphoresis was another means of ex-
pelling the unwanted humors from the body, 
and a tea made from the root bark o'f Sassafras 
served the purpose well. The overtaxed colo-
nist, as well as the physician , found use for this 
for an interesting reason. When English goods 
were boycotted in an attempt to repeal the 
Townsend Acts , there was a shortage of fine 
English tea, and Sassafras was substituted . The 
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colonists soon realized that Sassafras was better 
left off the shelf as a medicinal , but their desire 
for English goods did not stop a revolution. Al-
though diaphoresis was desirable, fevers were 
not, and for these, the sought-after remedy was 
cinchona or ' 'Peruvian bark. ' ' The colonial phy-
sician had the Jesuit missionaries to thank for 
recognizing its properties in curing malaria or 
relapsing fever . The active ingredient , not 
known at the time, was quinine, and today a de-
rivative of it , namely quinidine, is used as an 
antiarrhythmic and as a means to relieve 
muscle cramps. 
Cathartics, also known as purgatives, 
were a great mainstay of treatment, and the co-
lonial physician frequently relied on botanical 
remedies such as jalap , ipecacuanha, and rhu-
barb. In some instances, cathartic concoctions 
were significantly popular to carry the name of 
the originator. One example is P: Rudii, a rolled 
pill named after Eustachius Rudius, and it con-
tained colocynth (also known as bitter apple 
and bitter cucumber) , Scammony (residue of 
the plant Convo/vu/us Scammonia) , Turpeth 
root , Socotrine aloes (from an aloin); cinnamon , 
cloves, spirits of wine , salt of tartar , and Black 
Helebore root. It was claimed that it was even 
effective in the treatment of some " social dis-
eases." 
Pain relievers and sedatives were just as 
much in demand then as they are today, and 
opium headed the list. The abundant ' 'James-
towne weed ,' ' Datura stramonium was the local 
source of a narcotic-like drug . It was a sedative 
and anti-spasmodic in small doses, but in 
higher doses it was hallucinogenic , though colo-
nists praised this plant for its "cooling effects ." 
For the more minor pains, the physician might 
rely on a local anesthetic ; for example, the pain 
of a common sore throat was relieved by a 
gargle prepared from alum . In colonial days a 
more drastic use of alum was to pack the uterus 
in case of post-partum hemorrhage, but in mod-
ern times it is a spice used in canning. 
No list of medicines would be complete 
without mentioning three of the more all-pur-
pose substances praised by the early colonists 
and used by the colonial physician to maintain 
his patients ' general well-being . Po/yga/a Virgi-
nina, better known as seneca rattlesnake root 
was considered a reliable treatment. Its appli-
cation was varied , and its reputation , according 
to William Byrd II , "increases every day." Byrd 
noted that, ''The tincture of it has done wonders 
in the gout------ . By its purging, its diuretick, and 
diaphoretick qualities it is of great use in the 
dropsy----- of great efficacy in Pleuretick Feaver 
------ (and) a specifick against worms------ for the 
pite of a mad dog------ it may be perhaps as 
sure a remedy, as for the bite of a rattlesnake.'' 
Byrd also commented on the attributes of 
the popular aromatic licorice-like woodland 
herb , ginseng: "The earth has never produced 
any vegetable so friendly to man as Ginseng. I 
tiave found it very cordial and reviving after 
great fatigue , it warms the blood, frisks the spir-
its, strengthens the stomach and comforts the 
bowels exceedingly. All this it performs without 
any of those naughty effects that might make 
men too troublesome to their poor wives. ' ' 
Although the colonial physician may not 
have recognized the lack of medicinal value of 
rattlesnake root and ginseng , he probably never 
doubted the increasing popularity of tobacco. 
Tobacco was the New World plant that would 
make men rich. Little did the early colonist 
guess its future role in medicine. Tobacco was 
not only profitable as a luxury commodity but 
also as a remedy, for it "purgeth superfluous 
fleame and· other gross humors, openeth all the 
pores and passages of the body .. . . '' It was 
also claimed that tobacco could heal gout and 
ague, cure hangovers, and reduce fatigue and 
hunger. Of the more than 2,000 agents identi-
fied in tobacco, the best known is nicotine, 
which may decrease fatigue and curb the appe-
tite . Despite the custom of not inhaling, the sev-
enteenth-century smoker spent much more time 
tending his long slender pipe which may have 
kept him from falling asleep or eating too much . 
Tobacco probably did little for the colonist's 
swollen great toe or the fevers of malaria. Who 
would have thought that such a profitable weed 
could lead to some of the terminal diseases of 
today? 
The colonists were certainly imaginative in 
their approach to medical treatment, drawing 
both on the standard remedies , as well as na~ 
tive plants. What emerged was a multi-specialist 
apothecary-physician , vital to the community as 
were cultivation and identification of the local 
plants to him . One has only to think of how fre-
quently digitalis is prescribed to realize that 
even as modern physicians without an herb gar-
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den in our backyard, we certainly have one in 
our doctor's bag . 
Transcribed from a talk given in a Senior Elective in the His-
tory of Medicine at the Medical College of Virginia, May 
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